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Abstract 
Objectives 
The main aim of the study was to investigate the clinical and humanistic impact of 
pharmaceutical care intervention led by clinical pharmacist in adult patients with asthma. 
Methods 
This is a prospective randomized control study that was conducted in outpatient clinic at Al 
Makassed hospital. At baseline the number of patients who participated in the study were 106 
and 137 patients in the control and intervention groups, respectively. At 6 months, 101 and 122 
patients were in the control and intervention groups, respectively. Finally, at 12 month 90 and 
102 patients were in the control and intervention groups, respectively. This study was a 12 month 
trial during the period from September 2014 to September 2015; the Patients were randomized 
using computer generated random numbers. 
Patients were divided into the intervention group who received pharmaceutical care through 
asthma education, medication counselling, instructions, asthma care diary, etc., and the control 
group who were not provided any pharmaceutical care.  
Intervention patients received comprehensive medication counselling and asthma education 
every 3 months, while the control group received the routine medical consultation and dispensing 
services. The outcome measures were recorded using structured forms at baseline and monitored 
during a follow-up at 6 and 12 months in both groups. Data were analyzed using SPSS version 
22, level of significance was p<0.05. 
Results 
At the end of the study period, the intervention group showed a significant greater improvement 
in the score for assessing the inhalation technique and the proportion of patients who 
demonstrated appropriate inhaler technique (score = 7-10) was 31 (30.6%) in control group and 
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113 (92.6%) in intervention group with a significant p- value = 0.0001 but at 12 month the 
proportion of patients who demonstrated appropriate inhaler technique was slightly decreased 
about 88(86.2%) in intervention group and 32(35.5%) in control group, with p-value = 0.021.The 
knowledge scores improved in the intervention group, whereas there was evidence of 
deterioration in the control patient group. 
In the Asthma Control Test (ACT), the intervention had significantly increased the ACT after 6 
months compared with usual care, the proportion of the complete asthma control was 19(15.5%) 
and 5(4.9%) in intervention and control groups, respectively with p-value = 0.002 but the 
proportion of the controlled asthma was decreased at the 12 months about 9(8.8%) in 
intervention group and 7(7.7%) in control group, with non-significant p value = 0.077. 
In adherence to medications during the course of the study, patients were classified as adherent, 
non-adherent or moderate adherence. At baseline the results showed that the patients in the 
intervention group had the same adherence to medication compared to control group 5(3.64%), 
6(5.6%) respectively, with no significant improvement p value = 0.736. 
 
At 6 month, the percentage of adherence to non-adherence medication in intervention group 
were18(14.7%) and 25(20.4%), compared to control group, about 4(3.9%) were adherent and 
46(45.5%) were non-adherent to medications with a p value = 0.0003. 
 
At 12 month the adherence to medication was about 10(9.8%), and non-adherent was about 
30(29.4%) in intervention group compared to control group with 3(3.3%) were adherent and 
42(46.6%) were non-adherent to medications in control group and the p value was 0.021. 
There was no significant difference in continued asthma severity values between both groups 
about 15(14.1%) in control group and 22(16%) in intervention group, with (p value=0.227). But 
at 12 month there were a highly significant improvements in continued asthma severity values 
about 3(2.94%) in intervention group and 10(11.11%) in control groups with p-value=0.001. 
At the 12-month follow-up, patients in the intervention group had a significant reduction in both 
hospital admissions (15 vs. 36) visits with P- value =0.03 and ED visits (29 vs 58) visits with P- 
value =0.01 and 0.03 respectively. There was no significant difference in GP visits between 
v 
control and intervention group (P =0.11). The overall length of hospital stay was significantly 
lower in the intervention group (49 days) while in control group around (124 days). 
Conclusion 
The present findings suggest that pharmacist‘s intervention can have positive impact on asthma-
related outcomes in patients, in inhalation technique the intervention group showed a significant 
greater improvement in the score for assessing the inhalation technique relative to control group. 
In the Asthma Control Test (ACT), the intervention had significantly increased the ACT after 6, 
12 months compared with usual care in control group, in addition the adherence to medications 
during the course of the study showed that the patients in the intervention group had more 
significant adherence to medication compare to control group. 
Also in asthma severity values in intervention group are more significant than control group, and 
the patients in the intervention group had a significant reduction in both hospital admissions days 
compared to control group. 
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Chapter one 
1. Introduction 
1.1 Background 
 
Asthma is a common disease that leads to significant degrees of morbidity and mortality. 
Nowadays, it is estimated that as many as 300 million people of all ages, and all ethnic 
backgrounds suffer from asthma and the burden of this disease to government, healthcare 
systems, families, and patients is increasing worldwide. It is estimated that there may be an 
additional 100 million persons with asthma by 2025 [1]. Nonetheless, based on the application of 
standardized methods to measure the prevalence of asthma and wheezing illness in children [2] 
and adults [3], it shows that the global prevalence of asthma ranges from 1% to 18% of the 
population in different countries. Figure (1). 
 
Figure (1): Prevalence of asthma in different countries 
 
 
 
In the Middle East, asthma prevalence is reported to be lower than developed countries (ranges 
5–23%) [4-7]. Also in rural Palestinian, the lowest 12 month wheezing prevalence rate was 
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seen(5.5%) [7]. In neighboring countries like Jordan the prevalence rate for asthma was (4.1%) 
while wheezing was (8.9%) [5] and the highest prevalence rate was seen in desert population of 
Saudi Arabia (23%) [8] and in Baghdad (25%) [9]. 
In other nearby countries such as Turkey the prevalence rate for asthma was seen to be (14.1%) 
[10],United Arab Emirates (UAE) was (13%) [11], and in Lebanon (12%) [12] . 
However, in Israel, whose people share the same (outdoor) environment as Palestine, the 12-
months prevalence of wheezing was 17.8%. and Shohat et al.[6] indicated that this observed 
difference in the prevalence of asthma and asthma symptoms between Arabs and Jews might 
give a clue to the pathogenesis of asthma. 
Based on the reported, asthma is the most common chronic disease, this represent a major 
worldwide public health issue and the basis risk in asthma is acute exacerbations (asthma 
attacks), this is because a deterioration in symptoms control and objective measures of airflow 
obstruction [14]. 
1.2 Definition of asthma: 
Asthma is a disorder defined by its clinical, physiological, and pathological characteristics of 
episodic shortness of breath due to airway obstruction that make expiratory airflow limitation, 
particularly at night, often accompanied by cough is the most predominant feature of the clinical 
and physiological history of asthma and the most common physical finding is wheezing 
auscultation of the chest. 
The main dominant pathological feature seen in asthma is airway inflammation, sometimes 
associated with airway structural changes. People with asthma characterized by inflamed 
airways. This leads to airways swollen and very sensitive, especially when react strongly to 
certain substances that are breathed in as shown in figure (2). 
 
This means that when the airways react, the muscles around them tighten, and this leads to the 
airways to narrow, thus less air flows to the lungs. The swelling may worsen making the airways 
narrower. Also the cells located in the airways may secret mucus more than normal. This mucus 
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characterized by sticky, thick liquid that can narrow the airways, so this lead to  asthma 
symptoms and these symptoms can happen each time the airways are irritated [15]. 
Commitment use the appropriate treatment of asthma surely leads to control the clinical 
manifestations of asthma symptoms, sleep disturbances, limitations of daily activity, impairment 
of lung function and this control leads to rare occasional recurrence of symptoms and severe 
exacerbations [13]. 
 
Figure (2): Characteristics of lung in asthma. 
 
 
 
1.3 Causes of asthma: 
 
The exact and main cause of asthma is not known, so asthma can‘t be cured but it can be 
prevented and controlled. So with a good asthma management, the symptoms become free and 
the patient will enjoyed in all life and well become active. 
 
There are different factors that influence the risk of asthma and can be divided into those that 
cause the development of asthma that include host factors (which are primarily genetic) and 
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those that trigger asthma symptoms that are usually environmental factors; and some do both 
[16]. However, the mechanisms of how they influence the development and expression of 
asthma are complex and interactive. For example, to determine asthma susceptibility genes likely 
interact both with other genes and with environmental factors [17]. In addition, there are other 
important factors that modify the risk of asthma in genetically susceptible patients such as 
developmental aspects like the maturation of the immune response and the timing of infectious 
exposures during the first years of life. 
Because the lack of a clear definition for asthma presents there are a significant problem in 
studying the role of different risk factors in the development of this complex disease, so there are 
different factors that influence the causes of asthma divided to: 
 
1.3.1 Host factors. 
 
1.3.1.1 Allergen: 
 
Although there are indoor and outdoor allergens and they cause asthma exacerbations, their 
allergens specific role in the development of asthma is still not fully resolved. 
 Different studies have shown sensitization to house dust mite allergens, cat dander, dog dander 
and Aspergillus mold are independent risk factors for asthma [26]. However, the relationship 
between allergen exposure and sensitization in patient is not straightforward. It may depend on 
the allergen, the dose, the time of exposure, the patient‘s age or may be related to genetic factors. 
In addition, the prevalence of sensitization appears with direct exposure to allergens such those 
derived from house dust mites and cockroaches [2]. However, although some studies suggest that 
exposure to house dust mite allergens may be a causal factor in the development of asthma [27]; 
others have questioned this interpretation.  
1.3.1.2 Genetics: 
 
Asthma is not a simple disease, it has a heritable component. Based on different studies. More 
than one gene can lead to asthma [18].  these genes can develop asthma by production specific 
IgE antibodies, hyper-responsiveness of the airway, release of inflammatory mediators like 
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cytokines, and determination the ratio between Th1 and Th2 immune responses (as relevant to 
the hygiene of asthma) [19].  
 
Family studies show that there are a chromosomal regions associated with asthma susceptibility. 
For example, a tendency to produce an elevated level of total serum IgE is co-inherited with 
airway hyper-responsiveness, and a gene (or genes) governing airway hyper-responsiveness is 
located near a major locus that regulates serum IgE levels on chromosome 5q [20]. However, the 
search for a specific gene (or genes) involved in susceptibility to IgE antibodies or asthma 
continues [18]. 
1.3.1.3 Gender: 
 
The differences that we related to sex are not clear. However, the lung size at birth is smaller in 
males than females but at adulthood it is larger [25]. 
 
In addition, males have a risk factor for asthma in children. Prior to the age of 14, the prevalence 
of asthma is nearly twice as great in boys as in girls [24]. Also the difference in asthma between 
the sexes narrows when children get older, the prevalence of asthma is greater in women than in 
men by adulthood. 
1.3.1.4 Obesity and Diet:  
 
Obesity plays an important role as a risk factor for asthma. Leptins as a mediators may affect 
airway function and increase the likelihood of asthma development [23]; diet and breast feeding 
play an important role in developing asthma as shown in different studies, so the data reveals that 
infants fed formulas of intact cow's milk or soy protein have a higher incidence of wheezing 
illnesses in early childhood compared with those fed breast milk [27]. 
 
Nevertheless, some data suggesting  that certain characteristics of Western diets, such as 
increased use of processed foods and decreased antioxidant (in the form of fruits and vegetables), 
increased n-6 polyunsaturated fatty acid (found in margarine and vegetable oil) and decreased n-
 7 
3 polyunsaturated fatty acid (found in oily fish) intakes have contributed to the recent increases 
in asthma [22]. 
1.3.1.5 Occupational allergens:  
 
Asthma is the most common occupational respiratory disorder in industrialized countries [2]. 
Farming and agricultural work, painting (including spray painting), cleaning work, and plastic 
manufacturing are the most common occupations associated with high risk for asthma [27]. 
The exposure to an agent encountered in the work environment has been associated with over 
300 substances that causes asthma [17]. These substances include highly reactive small 
molecules such as isocyanates, irritants that may alter airway responsiveness, known 
immunogens such as platinum salts, and complex plant and animal biological products which 
lead to stimulation in IgE production(Table 1). Occupational asthma arises predominantly in 
adults [18] and about 1 in 10 cases of asthma among adults of working age are estimated to be 
caused by occupational sensitizers [19]. 
 
However, the factors that sensitize some people but not others to develop occupational asthma in 
response to the same exposures are not well identified. ―Irritant induced asthma‖ (formerly called 
the reactive airways dysfunctional syndrome) may be due to very high exposure to inhaled 
irritants even in non-atopic persons. Tobacco smoking may increase the risk of occupational 
sensitization, but screening individuals for atopy is of limited value in preventing occupational 
asthma [28]. Elimination or reduction of exposure to occupational sensitizers seems to be the 
most important method of preventing occupational asthma. 
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Table (1): Causes of occupational asthma 
 
Agent Occupations Agent Occupations 
Animal products: 
 Dander. 
 Excereta. 
 Serum. 
 Secretions. 
 Animal 
handlers. 
 Laboratory 
workers. 
 Veterinarian
s. 
Metals: 
 Platinum. 
 Nickel. 
 Cobalt. 
 Vanadium. 
 
 Platinum 
and Nickel 
refining 
workers. 
 Hard metal 
worker. 
 
 
Plants: 
 Grain. 
 Flour. 
 Tobacoo. 
 Hops. 
 Dust. 
 
 Grain 
handlers. 
 Tea 
workers. 
 Bakers. 
 Natural oil 
manufacturi
ng workers. 
 Healthcare 
workers. 
 
 Soldering 
fluxes 
 Solderers. 
Anhydrides: 
 Phthalic anhydrates. 
 Trimelliticanhydrates. 
 Epoxy resin 
and plastics 
workers. 
Wood dust: 
 Oak. 
 Mahogany. 
 California. 
 Carpenters. 
 Sawmill 
workers. 
 Furniture 
workers. 
Vegetables: 
 Gum acacia. 
 Gum tragacanth. 
 Printers. 
 Gum 
 Manufacturi
ng workers. 
Others: 
 Crab. 
 Prawn. 
 Crab and 
Prawn 
processors. 
 
1.3.1.6Environmental factors: 
 
There are a relationship between environmental factors that influence the risk of developing 
asthma and factors that cause asthma symptoms for example, occupational sensitizers that belong 
to this both categories. In addition, air pollution and some allergens there are some important 
causes of asthma symptoms such as air pollution and some allergens which have not been clearly 
linked to the development of asthma. 
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1.3.1.7 Infections: 
 
There are a numerous number of viruses associated with the inception of the asthmatic 
phenotype during infancy such viruses are: Respiratory syncytial virus (RSV) and para-influenza 
virus that produce a different symptoms including bronchiolitis in childhood asthma. Several 
studies show that about 40% of children who was admitted to the hospital as a result of RSV will 
continue to wheeze or may have asthma into later childhood [28].  On the other hand, a certain 
respiratory infections early in life, such as measles and sometimes even RSV, may be protect 
against the development of asthma [23].  
 
The ―hygiene hypothesis‖ of asthma suggests that when the patients exposure to infections early 
in life this lead to the development of a child‘s immune system along a ―non-allergic‖ pathway, 
leading to a reduced the risk of asthma and other allergic diseases. Although the hygiene 
hypothesis continues to be investigated, this mechanism may explain observed associations 
between family size, birth order, day care attendance, and the risk of asthma. 
 
1.3.1.8 Smoking: 
 
Tobacco smoking is associated with accelerated decline of lung function in people with asthma, 
increases asthma severity, and may decrease the control of  likelihoodfor asthma and render 
patients less responsive to inhaled and systemic glucocorticosteriods[20]. 
The exposure to tobacco smoke both in prenatally and after birth lead to the harmful effect 
including a greater risk of developing asthma like symptoms in early childhood [16]. 
Although distinguishing the independent contributions of prenatal and postnatal maternal 
smoking is problematic. According to that , there are different studies related to a lung function 
immediately after birth have shown that maternal smoking during pregnancy has an influence on 
lung development and found that  infants of smoking mothers are 4 times more likely to develop 
wheezing illnesses in the first year of life [17]. 
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1.4 Diagnosis of asthma: 
 
Asthma is a very common condition all over the world with a high level of awareness and it is 
the most common cause of chronic respiratory symptoms in young adult. 
The key diagnostic indicators are a history of cough, wheeze, shortness of breath and airway 
obstruction; either spontaneously over time or in response to treatment.  
Asthma symptoms may be intermittent and their significance may be overlooked by patients and 
physicians, or because they are non-specific, they may result in misdiagnosis. 
1.4.1 Symptoms of asthma: 
 
 A clinical diagnosis of asthma is often prompted by symptoms such as episodic breathlessness, 
wheezing, cough, and chest tightness. There are different diagnostic guides that play an 
important role in diagnosis of asthma such as episodic symptoms after an incidental allergen 
exposure, seasonal variability of symptoms and a positive family history of asthma and atopic 
disease. Asthma associated with rhinitis may occur intermittently, with the patient being entirely 
asymptomatic between seasons or it may involve seasonal worsening of asthma symptoms or a 
background of persistent asthma. Because of these different symptoms the asthma diagnosis are 
variability; and appropriate asthma therapy is needed [28]. 
1.4.2Exercise induced asthma: 
 
Physical activity play an important is an important cause of asthma symptoms in most asthma 
patients, and for some it is the only cause. 
Exercise induced bronchoconstriction typically develops for example when running as main 
potent triggers within 5-10 minutes after completing exercise. The asthma symptoms and 
troublesome cough will resolve spontaneously within 30-45 minutes [17]. The more common 
condition that led to the Exercise induced bronchoconstriction  when the patient is breathing dry, 
cold air and less common in hot, humid climates [18]. 
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1.4.3 Cough variant asthma: 
 
Patients with cough variant asthma have chronic cough. It is common in children, and it  worsen 
at night; but during the day becomesnormal. So these patients have a variability in lung function 
or of airway hyper-responsiveness, and possibly a search for sputum eosinophils, are particularly 
important [23]. So patients with Cough variant asthma must be distinguished from called 
eosinophilic bronchitis in which patients have cough and sputum eosinophils but normal indices 
of lung function when assessed by spirometry and airway hyper-responsiveness [13]. 
There are different things considered as cough induced such angiotensin converting enzyme 
(ACE) inhibitors, gastroesophageal reflux, postnasal drip, chronic sinusitis and vocal cord 
dysfunction [16]. 
 
1.5 Tests for diagnosis and monitoring of asthma: 
1.5.1 Measures of lung function: 
 
The diagnosis of asthma is mainly depends on the presence of characteristic symptoms. 
However, measurements of lung function, and particularly the demonstration of reversibility of 
lung function abnormalities, greatly enhance diagnostic confidence. This is because patients with 
asthma frequently have poor recognition of their symptoms and poor perception of symptom 
severity, especially if their asthma is long-standing [2]. Assessment of symptoms such as 
dyspnea and wheezing by physicians may also be inaccurate [27]. 
 
There are various methods that are available to assess airflow limitation. For example; 
spirometry, particularly the measurement of forced expiratory volume in 1 second (FEV1) and 
forced vital capacity (FVC), and peak expiratory flow (PEF) measurement. 
These Predicted values of FEV1, FVC, and PEF based on age, sex, and height have been 
obtained from population studies and being continually revised.  
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1.5.2Spirometer: 
 
It is the usual recommended method of measuring airflow limitation and reversibility to establish 
a diagnosis of asthma. Measurements of FEV1 and FVC are undertaken during a forced 
expiratory using a spirometer as shown in figure (3). 
 
Recommendations for the standardization of spirometry have been published [22]. The degree of 
reversibility in FEV1 which indicates a diagnosis of asthma is generally accepted as ≥12% (or 
≥200 ml) from the pre-bronchodilator value 13. However most asthma patients will not exhibit 
reversibility at each assessment, particularly those on treatment, and the test therefore lacks 
sensitivity. 
 
Spirometry is reproducible, and effort dependent, thus proper instructions on how to perform the 
forced expiratory maneuver must be given to patients, and the highest value of three recordings 
taken. Repeated testing at different visits is advised and because the differences in spirometric 
values have been demonstrated, appropriate predictive equations for FEV1 and FVC should be 
established for each patient. The normal range of values is wider and predicted values are less 
reliable in young people (< age 20) and in the elderly (> age 70). Because many lung diseases 
may result in reduced FEV1, a useful assessment of airflow limitation is the ratio of FEV1 to 
FVC. The FEV1/FVC ratio is normally greater than 0.75 to 0.80, and possibly greater than 0.90 
in children. Any values less than these suggest airflow limitation. 
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Figure (3): Spirometry measurement 
 
 
 
1.5.3 Peak expiratory flow (PEF): 
 
Peak flow meter measurements aid in diagnosis and monitoring of asthma. A modern PEF 
meters can be used at home settings for day-to-day objective measurement of airflow limitation. 
Therefore they are relatively inexpensive, portable, plastic and ideal. However, measurements of 
PEF are not interchangeable with other measurements of lung function such as FEV1 in either 
adults or children [28].  
 
PEF can underestimate the degree of airflow limitation, particularly as airflow limitation and gas 
trapping worsen. Because values for PEF obtained with different peak flow meters vary and the 
range of predicted values is too wide, PEF measurements should preferably be compared to the 
patient‘s own previous best measurements using his/her own peak flow meter [23]. The previous 
best measurement is usually obtained when the patient is asymptomatic or on full treatment and 
serves as a reference value for monitoring the effects of changes in treatment, the previous best 
measurement is usually obtained. 
 
Careful instruction is required to reliably measure PEF because PEF measurements are effort-
dependent. Most commonly, PEF is measured first thing in the morning before treatment is 
taken, when values are often close to their lowest,and last thing at night when values are usually 
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higher. One method of describing diurnal PEF variability is as the amplitude (the difference 
between the maximum and the minimum value for the day), expressed as a percentage of the 
mean daily PEF value, and averaged over 1-2 weeks. Another method of describing PEF 
variability is the minimum morning pre-bronchodilator PEF over 1 week, expressed as a percent 
of the recent best (Min%) [15]. This latter method has been suggested to be the best PEF index 
of airway labiality for clinical practice because it requires only a once-daily reading, correlates 
better than any other index with airway hyper-responsiveness, and involves a simple calculation. 
1.6 Classification of asthma: 
 
Many attempts have been made to classify asthma according to etiology, particularly with 
regards to environmental sensitizing agents. And despite, such a classification is limited by the 
existence of patients in whom no environmental cause can be identified. Still an effort to identify 
an environmental cause for asthma (for example, occupational asthma) should be part of the 
initial assessment to enable us to adapt avoidance strategies in asthma management. Describing 
patients as having allergic asthma is usually of little benefit, since single specific causative 
agents are seldom identified. 
 
1.6.1 Asthma severity: 
 
A four categories of asthma were subdivided by the previous GINA documents by severity based 
on the level of symptoms, airflow limitation, and lung function variability: Intermittent, Mild 
persistent, moderate persistent, or severe persistent [29] (Table 2). Classification of asthma by 
severity is useful when decisions are being made about management at the initial assessment of a 
patient. It is important to recognize, however, that asthma severity involves both the severity of 
the underlying disease and its responsiveness to treatment [16]. Thus, asthma can present with 
severe symptoms and airflow obstruction and be classified as Severe Persistent on initial 
presentation, but respond fully to treatment and then be classified as Moderate Persistent asthma. 
In addition, asthma may change over months or years as its severity is not an unvarying feature 
of an individual. 
 
 
 15 
Table (2): GINA classification of asthma severity 
 
 Symptoms/day Symptoms/night 
PEF or 
FEV1 
PEF  
variability 
Step 1 
Intermittent 
 
 <1 time a week. 
 Asymptomatic 
and normal PEF 
between attack. 
 
<or = 2 times a 
month. 
> or =80% < 20% 
Step 2 
Mild 
persistent 
 
 >1 time a week 
but <1 time a day. 
 Attack may affect 
activity. 
 
> 2 times a 
month. 
> or =80% 20-30% 
Step 3 
Moderate  
persistent 
 
 Daily. 
 Attack 
affectsactivity. 
 
> 1 time a week. 60-80% > 30% 
Step 4 
Severe 
persistent 
 
 Continuous. 
 Limited physical 
activity. 
 
Frequent. < or = 60% > 30% 
PEF: Peak expiratory flow, FEV1: Forced expiratory volume in the first second. 
 
1.6.2Asthma Control: 
 
There is evidence that reducing inflammation with controller therapy achieves clinical control, 
but because of the cost and/or general unavailability of tests such as endobronchial biopsy and 
measurement of sputum eosinophils and exhaled nitric oxide [17], it is recommended that 
treatment be aimed at controlling the clinical features of disease, including lung function 
abnormalities. (Table 3) provides the characteristics of controlled, partly controlled and 
uncontrolled asthma. Complete control of asthma is commonly achieved with treatment, the aim 
of which should be to achieve and maintain control for prolonged periods with due regard to the 
safety of treatment, potential for adverse effects, and the cost of treatment required to achieve 
this goal [18]. 
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Table (3): Characteristics of controlled, partly controlled and uncontrolled asthma. 
 
1.7 Asthma medications(controllers and relievers): 
 
The effectiveness of drug therapy in asthma has been established for many years, it remains the 
mainstay of asthma management, and almost all adults of asthma will benefit from some form of 
drug therapy. So the goal of asthma treatment is to achieve and maintain clinical control in order 
to improve quality of life for the patients. Medications as seen in figure (4) to treat asthma can 
be classified as controllers or relievers.  
 
 
 
 
 
 
 
 
 
Characteristic Controlled Partly controlled Uncontrolled 
Daytime symptoms 
None (twice /less a 
week) 
More than twice a week 
3 or more 
features of 
partly controlled 
asthma 
Limitation of activities None Any  
Nocturnal symptom None Any  
Need for 
relieve/rescue 
treatment 
None (twice /less a 
week) 
More than twice a week  
Lung function(FEV or 
PEF) 
Normal 
<80%predicted or 
personal best(if known) 
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Figure (4): Asthma step up treatment chart (GINA) 
 
Controllers are medications taken daily on a long-term basis so they are the opposite of as 
needed of PRN medication to keep asthma under clinical control mainly through their anti-
inflammatory effects. They include inhaled and systemic (including oral and intravenously 
medication) glucocorticosteroids, leukotriene modifiers, long acting inhaled β2-agonists in 
combination with inhaled glucocorticosteroids, sustained release theophylline, cromones, anti-
IgE, and other systemic steroid sparing therapies. Inhaled glucocorticosteroids are the most 
effective controller medications currently available for treatment of persistent asthma. 
 
Relievers are medications used on an as needed basis that act quickly to reverse bronchospasm 
during acute exacerbation and relieve its acute symptoms. They include short acting inhaled β2-
agonists (SABA), inhaled anticholinergics, short acting theophylline, and short acting oral β2-
agonists. 
 
Asthma treatment for adults can be administered in different ways inhaled, orally or parenterally 
(by subcutaneous, intramuscular, or intravenous injection), usually inhaled therapy is the most 
common way for asthma treatment. The major advantage of inhaled therapy is that drugs are 
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delivered directly into the airways, producing higher local concentrations into the lungs with 
significantly less risk of systemic side effects especially for glucocorticoids treatment. 
Inhaled medications for asthma are found for different types as pressurized metered-dose 
inhalers (MDIs), breath actuated MDIs, dry powder inhalers (DPIs), soft mist inhalers, and 
nebulized or Wet aerosols. Inhaler devices differ in their efficiency of drug delivery to the lower 
respiratory tract, many factors interfere in their efficacy including; form of the device, 
formulation of medication, particle size, velocity of the aerosol cloud or plume (where 
applicable), and ease with which the device can be used by the majority of patients. Individual 
patient preference, convenience, and ease of use may influence not only the efficiency of drug 
delivery but also important for patient adherence and compliance to treatment and long-term 
control. 
 
Pressurized MDIs (pMDIs) require training and skill to coordinate activation of the inhaler and 
inhalation, take cap off, breath out, hold 1-2 inch away from your mouth or on your mouth 
between your lips, start breathing, then press bottom, breath slowly and deeply, hold your breath 
for 10 seconds then breath out slowly. 
 
Medications in these devices can be dispensed as a suspension in chlorofluorocarbons (CFCs) or 
as a solution in hydrofluoroalkanes (HFAs). For a pMDI containing CFCs, the use of a spacer 
(holding chamber) improves drug delivery, increases lung deposition, and may reduce local and 
systemic side effects, spacer reduce deposition of particles in oropharynx this reduce absorption 
from gastrointestinal tract which thing reduce system bioavailability thus reduce systemic side 
effect [30]. However, CFC inhaler devices are being phased out due to the impact of CFCs upon 
the atmospheric ozone layer, and are being replaced by HFA devices. For pMDIs containing 
bronchodilators, the switch from CFC to HFA inhalers does not result in a change in efficacy at 
the same nominal dose [31].  
 
However, for some glucocorticosteroids, the HFA formulations provide an aerosol of smaller 
particle size that results in less oral deposition (with associated reduction in oral side effects), 
and correspondingly greater lung deposition which is an advantage over CFC. 
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This may result in greater systemic efficacy at equivalent ex-actuator doses, but also greater 
systemic exposure and risk of side effects [32, 33].  
Pressurized MDIs may be used by patients with asthma of any severity, including during 
exacerbations. Breath actuated aerosols may be helpful for patients who have difficulty using the 
―press and breathe‖ pressurized MDI [2]. 
 
Soft mist inhalers appear to require less coordination. Dry powder inhalers are generally easier to 
use, but they require a minimal inspiratory flow rate and may prove difficult for some patients. 
DPIs differ with respect to the fraction of ex-actuator dose delivered to the lung. For some drugs, 
the dose may need to be adjusted when switching from an MDI to a DPI they are not 
exchangeable [27].  Nebulized aerosols are rarely indicated for the treatment of chronic asthma 
in adults [34]. 
 
1.7.1 Controller medications: 
1.7.1.1 Long acting inhaled β2-agonists (LABA):  
 
Long-acting inhaled β2-agonists, including formoterol and salmeterol, should not be used as 
monotherapy in asthma as these medications do not appear to influence the airway inflammation 
in asthma usually there are combined with glucocorticosteroids. 
 
They are most effective when combined with inhaled glucocorticosteroids[49], and this 
combination therapy is the preferred treatment when a medium dose of inhaled 
glucocorticosteroid alone fails to achieve control of asthma in moderate severe asthma. Addition 
of long-acting inhaled β2-agonists to a daily regimen of inhaled glucocorticosteroids improves 
symptom scores, decreases nocturnal asthma, improves lung function, decreases the use of rapid-
acting inhaled β2-agonists [50], reduces the number of exacerbations [50], and achieves clinical 
control of asthma in more patients, more rapidly, and at a lower dose of inhaled 
glucocorticosteroids than inhaled glucocorticosteroids given alone, thus reduce risk of asthma 
exacerbation [51]. 
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This greater efficacy of combination treatment has led to the development of fixed combination 
inhalers that deliver both glucocorticosteroid and long acting β2-agonist simultaneously 
(fluticasone propionate plus salmeterol, budesonide plus formoterol). Controlled studies have 
shown that delivering this therapy in a combination inhaler is as effective as giving each drug 
separately [27]. Fixed combination inhalers are more convenient for patients, may increase 
compliance [52], and ensure that the long acting β2-agonist is always accompanied by a 
glucocorticosteroid. In addition, combination inhalers containing formoterol and budesonide may 
be used for both rescue and maintenance because formoterol has a rapid onset of action almost 
similar to albetrol, because it is full agonist as albetrol. 
 
Both components of budesonide formoterol given as needed contribute to enhanced protection 
from severe exacerbations in patients receiving combination therapy for maintenance and 
provide improvements in asthma control at relatively low doses of treatment because formoterol 
rapid effect [53]. 
 
Long acting β2-agonists as formoterol may also be used to prevent exercise induced 
bronchospasm, and for this purpose may provide longer protection than rapid acting inhaled β2- 
agonists [54]. Salmeterol and formoterol provide a similar duration of bronchodilation (about 
12h the duration of action of asthma) and protection against bronchoconstrictors, but there are 
pharmacological differences between them. Formoterol has a more rapid onset its onset of action 
within 3 minutes, however salmeterol its onset of action 30-48 minutes [55], which may make 
formoterol suitable for symptom relief as well as symptom prevention[56]. 
 
The possible side effects when taking long acting inhaled β2-agonists is fewer systemic adverse 
effects, because they have local effect, however the systemic effect that may occur. Such as 
cardiovascular stimulation that may increase the risk of arrhythmia and electrocardiogram 
changes. Skeletal muscle tremor, and hypokalemia, this effect is usually transient than oral 
therapy. The regular use of rapid acting β2-agonists in both short and long acting forms may lead 
to relative refractoriness to β2-agonists [57]. Data indicating a possible increased risk of asthma 
related death associated with the use of salmeterol in a small group of individuals [58] led to 
advisories from the US Food and Drug Administration (FDA) and Health Canada  that long 
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acting β2 agonists are not a substitute for inhaled or oral glucocorticosteroids, and should only be 
used in combination with an appropriate dose of inhaled glucocorticosteroid as determined by a 
physician. A study has identified that the asthma of subjects with an unusual genotype for the 
beta-adrenergic receptor (with substitution of arginine for glycine at position B16) may 
deteriorate with regular use of salmeterol whether or not administered with inhaled 
glucocorticosteroids, also formoterol alone many increase risk of asthma exacerbation and these 
increase mortality [21]. 
1.7.1.2Theophylline:  
 
Theophylline is a bronchodilator and, when given in a lower dose, has modest anti-inflammatory 
properties [59]. It is available in sustained release formulations that are suitable for once or twice 
daily dosing. Data on the relative efficacy of theophylline as a long term controller is lacking. 
However, available evidence suggests that sustained release theophylline has little effect as a 
first line controller [60]. It may provide benefit as add on therapy in patients who do not achieve 
control on inhaled glucocorticosteroids alone [19].  
 
Additionally in such patients the withdrawal of sustained release theophylline has been 
associated with deterioration of control [61]. As add on therapy, theophylline is less effective 
than long acting inhaled β2-agonists, theophylline usually preferred in patients with respiratory 
center depression, or in respiratory muscle weakness, sleep apnea, hyper-apnea[62]. 
 
The most common side effects of theophylline are gastrointestinal symptoms, loose stools, 
cardiac arrhythmias, seizures, and even death. Nausea and vomiting are the most common early 
events.  
1.7.1.3 Inhaled glucocorticosteroids (ICS): 
 
Inhaled glucocorticosteroids are currently the most effective anti-inflammatory medications for 
the treatment of persistent asthma, glucocorticosteroids considered as corn stone for controlling 
asthma. Studies have demonstrated their efficacy in reducing asthma symptoms, improving 
quality of life, reducing morbidity and improving lung function [35], decreasing airway hyper-
responsiveness, controlling airway inflammation, reducing frequency and severity of 
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exacerbations, and reducing asthma mortality [36]. However, they do not cure asthma they 
control it, and when they are discontinued deterioration of clinical control follows within weeks 
to months in a proportion of patients thus considered as long term treatments [37]. 
 
Inhaled glucocorticosteroids differ in potency and bioavailability, but because of relatively flat 
dose-response relationships or estimated equipoint daily doses. In asthma relatively few studies 
have been able to confirm the clinical relevance of these differences.  
 
The efficacy of some products varies when administered via different inhaler devices [38]. Most 
of the benefit from inhaled glucocorticosteroids is achieved in adults at relatively low doses, in 
order to achieve best treatment equivalent to 400 mg of budesonide per day, anti-inflammatory 
effect including reduce number of mast cells and eosinophils, increase number of receptors 
which increase effectiveness, improve receptor response, reduce mucus secretion and the 
hypersensitivity, reduces airway edema[27]. 
 
 Increasing to higher doses provides little further benefit in terms of asthma control but increases 
the risk of side effects [39]. However, there is marked individual variability of responsiveness to 
inhaled glucocorticosteroids and because of this and the recognized poor adherence to treatment 
with inhaled glucocorticosteroids, many patients will require higher doses to achieve full 
therapeutic benefit result in more adverse effect. As tobacco smoking reduces the responsiveness 
to inhaled glucocorticosteroids, higher doses may be required in patients who smoke, smoking 
usually will exacerbate asthma. 
 
The possible local side effects when takinginhaled glucocorticosteroids include oropharyngeal 
candidiasis which may occur in many patients, dysphonia, and occasionally coughing from upper 
airway irritation. For pressurized MDIs the prevalence of these effects may be reduced by using 
certain spacer devices [30]. 
 
Mouth washing (rinsing with water, gargling, and spitting out) after inhalation, is the best 
method which may reduce oral candidiasis. The use of prodrugs that are activated in the lungs 
but not in the pharynx (e.g. ciclesonide and beclometasone)[40], and new formulations and 
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devices that reduce oropharyngeal deposition, may minimize such effects without the need for a 
spacer that retain the large particles or mouth washing. 
1.7.1.4 Leukotriene modifiers:  
 
Leukotriene modifiers include cysteinylleukotriene 1 (CysLT1) receptor antagonists 
(montelukast, pranlukast, and zafirlukast) and a 5-lipoxygenase inhibitor (zileuton). Clinical 
studies have demonstrated that leukotriene modifiers have a small and variable bronchodilator 
effect, so they are not the first choice in asthma treatment  reduce symptoms including cough 
[40], improve lung function, and reduce airway inflammation and asthma exacerbations [22].  
 
They may be used as an alternative treatment for adult patients with mild persistent asthma [28], 
and some patients with aspirin sensitive asthma respond well to leukotriene modifiers also in 
smokers sometimes are much effective [41]. However, when used alone as controller, the effect 
of leukotriene modifiers are generally less than that of low doses of inhaled glucocorticosteroids, 
and, in patients already on inhaled glucocorticosteroids, leukotriene modifiers cannot substitute 
for this treatment without risking the loss of asthma control [42]. 
 
 Leukotriene modifiers used as add on therapy may reduce the dose of inhaled 
glucocorticosteroids required by patients with moderate to severe asthma this is advanced stages 
they can‘t be used alone or controller drugs [43], and may improve asthma control in patients 
whose asthma is not controlled with low or high doses of inhaled glucocorticosteroids[44]. With 
the exception of one study that demonstrated equivalence in preventing exacerbations [45], 
several studies have demonstrated that leukotriene modifiers are less effective than long-acting 
inhaled β2 agonists as add on therapy or as a combination with glucocorticoids [46, 47]. 
 
Leukotriene modifiers are well tolerated, and few if any class related effects have so far been 
recognized. Zileuton has been associated with liver toxicity as a side effect, so monitoring of 
liver function tests is recommended during treatment with this medication specially monitor 
serum  ALT (prior to initiation, once monthly for the first three month, then every 2-3 months for 
the first year). The apparent association of leukotriene modifiers with Churg Strauss syndrome 
(Eosinophilic granulomatosis with polyangititis) is probably largely the result of reductions in 
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the doses of systemic and or inhaled glucocorticosteroids unmasking the underlying disease, but 
a causal association in some patients cannot be entirely excluded [48]. 
 
1.7.1.5 Cromones: sodium cromoglycate and nedocromil sodium: 
 
The role of sodium cromoglycate and nedocromil sodium in long term treatment of asthma in 
adults is limited. Efficacy has been reported in patients with mild persistent asthma and exercise 
induced bronchospasm. Their anti-inflammatory effect is weak and they are less effective than a 
low dose of inhaled glucocorticosteroid[18]. 
 
The side effects are uncommon and include coughing upon inhalation and sore throat. Some 
patients find the taste of nedocromil sodium unpleasant. 
1.7.1.6 Long acting oral β2-agonists: 
 
 Long acting oral β2-agonists include slow release formulations of salbutamol, terbutaline, and 
bambuterol, a prodrug that is converted to terbutaline in the body. They are used only on rare 
occasions when additional bronchodilation is needed. 
 
The possible side effects when taking long acting oral β2-agonists is higher than that of inhaled 
β2-agonists, and includes cardiovascular stimulation (tachycardia), anxiety, and skeletal muscle 
tremor hypokalemia through intracellular shunting. Regular use of long-acting oralβ2-agonists as 
monotherapy is likely to be harmful and these medications must always be given in combination 
with inhaled glucocorticosteroids. 
1.7.1.7 Anti IgE (Omalizumab): 
 
AntiIgE (omalizumab) that prevents binding of IgE to mast cell is a treatment option limited to 
patients with elevated serum levels of IgE, given as subcutaneous every 2-4 weeks for 6 months. 
The dose and frequency based on body weight and pre-treatment of total IgE serum level, the 
dose should not be adjusted based on IgE level taking during treatment or less than one year 
following interruption of therapy. 
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Its current indication is for patients with severe allergic asthma who are uncontrolled on inhaled 
glucocorticosteroids, although the dose of concurrent treatment has varied in different studies. 
Improved asthma control is reflected by fewer symptoms, less need for reliever medications, and 
fewer exacerbations [63]. 
 
Further investigations will likely provide additional clarification of the role of anti IgE in other 
clinical settings. The main side effect is anaphylaxis that usually occurs within the first or second 
dose and with onset of ≤60 minutes up to four days, if anaphylaxis reaction does occur then the 
treatment needs to be discontinued. 
1.7.2Reliever medications: 
 
Reliever medications act quickly to relieve bronchoconstriction and its accompanying acute 
symptoms. 
1.7.2.1 Short acting inhaled β2 agonists(SABA): 
 
Short acting inhaledβ2-agonists are the medications of choice for relief of bronchospasm during 
acute exacerbations of asthma and as prophylaxis for the pre-treatment of exercise-induced 
bronchoconstriction. They include salbutamol, terbutaline, fenoterol, reproterol, and pirbuterol. 
Formoterol, a long acting β2-agonist, is approved for symptom relief because of its rapid onset of 
action, but it should only be used for this purpose in patients on regular controller therapy with 
inhaled glucocorticosteroids, because alone will increase risk of asthma exacerbation. 
Short acting inhaled β2-agonists should be used only on an as-needed basis at the lowest dose and 
frequency required. Increased use, as a reliever especially daily use, is a warning of deterioration 
of asthma control and indicates the need to reassess treatment either by increasing doses or 
adding another combination, Similarly, failure to achieve a quick and sustained response to β2-
agonist treatment during an exacerbation mandates medical attention, and may indicate the need 
for short term treatment with oral glucocorticosteroids . 
Uses of oral β2-agonists given in standard doses are associated with more adverse systemic 
effects such as tremor and tachycardia than occur with inhaled preparations that have less side 
effects. 
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1.7.2.2 Anti -cholinergics: 
 
Anticholinergic bronchodilators used in asthma include ipratropium bromide and 
oxitropiumbromide, they are on M2, M3 receptors with long duration of action six to eight hours. 
Inhaled ipratropium bromide is a less effective reliever medication in asthma than rapid acting 
inhaled β2- agonists. The benefits of ipratropium bromide in the long term management of 
asthma have not been established, although it is recognized as an alternative bronchodilator for 
patients who experience such adverse effects as tachycardia, arrhythmia, and tremor from short 
acting B2 agonists usually anticholinergics are preferred in patients with COPD. 
Inhalation of ipratropium or oxitropium can cause a dryness of the mouth and a bitter taste. 
There is no evidence for any adverse effects on mucus secretion [65]. 
1.7.2.3Systemic glucocorticosteroids: 
 
Systemic glucocorticosteroidscan be administered including oral or IV. However oral 
glucocorticosteroids are usually as effective as those administrated intravenously and are 
preferred because this route of delivery is less invasive and less expensive unless vomiting occur 
re-administrated intravenously. Although systemic glucocorticosteroids are not usually thought 
of as reliever medications, they are important in the treatment of severe acute exacerbations 
because they prevent progression of the asthma exacerbation, reduce the need for referral to 
emergency departments and hospitalization, prevent early relapse after emergency treatment, and 
reduce the morbidity of the illness. The main effects of systemic glucocorticosteroids in acute 
asthma are only evident after four to six hours. Oral therapy is preferred and is as effective as 
intravenous hydrocortisone[16]. 
 
 A typical short course of oral glucocorticosterods for an exacerbation is 40-50 
mg[64]prednisolone given daily for five to ten days depending on the severity of the 
exacerbation. When symptoms have subsided and lung function has approached the patient‘s 
personal best value, the oral glucocorticosteroids can be stopped or tapered, provided that 
treatment with inhaled glucocorticosteroids continues thus when patients discharge, after asthma 
exacerbation should take systemic (oral) glucocorticoids in order to reduce risk of relapse. 
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Intramuscular injection of glucocorticosteroids has no advantage over a short course of oral 
glucocorticosteroids in preventing relapse[16]. 
Adverse effects of shortterm highdose systemic therapy are uncommon but include reversible 
abnormalities in glucose metabolism, increased appetite, fluid retention, weight gain, rounding of 
the face, mood alteration, hypertension, peptic ulcer. 
1.7.2.4 Theophylline: 
 
 Short acting theophylline may be considered for relief of asthma symptoms, they are not 
prepared in sustained release formula in order to give fast onset of action [13]. The role of 
theophylline in treating exacerbations remains controversial. Short acting theophylline may 
provide no additive bronchodilator effect over adequate doses of rapid acting β2-agonists. 
1.7.2.5 Short acting oral β2-agonists:  
 
Short acting oral β2-agonists are appropriate for use in a few patients who are unable to use 
inhaled medications. This is due to a higher prevalence of adverse effects. 
 
Despite the availability of highly effective medication it remains a poorly controlled disease. 
Reasons for this poor control include non-implementation and inherent limitations of the asthma 
management guidelines, poor compliance with asthma therapy, incorrect use of inhaler devices 
and insufficient treatment of peripheral airway inflammation[66]. 
 In conclusion; medications for treatment of asthma are used to treat, prevent and control asthma 
symptoms, to reduce the number and severity of asthma episodes and to improve airflow. 
Asthma treatment includes the use of bronchodilators, mainly β2-adrenergic agonists, muscarinic 
receptor antagonists and corticosteroids or leukotriene antagonists as anti-inflammatory agents. 
These active drugs are administered either separately or given as a fixed dose 
combination medication into a single inhaler[67]. 
Inhaled therapy, still the cornerstone of asthma management, this is because its therapeutic 
agents are delivered directly to the lungs, the inhaled route offers a more rapid onset of action, 
allows smaller doses to be used and has a better efficacy to safety ratio compared to systemic 
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therapy. Long-acting β2-agonists (LABAs) and inhaled corticosteroids (ICS) have become the 
pharmacological mainstay of management programs, treating the symptoms of disease and the 
underlying inflammatory processes, respectively[68].Inhaled corticosteroids are delivered 
through a variety of devices including metered dose inhalers (MDIs), dry powder inhalers 
(DPIs), or nebulizer[69].Some of the commonly available devices are summarized in Table (4). 
Table(4): Common inhaled devices 
Type Device Advantages Disadvantages 
Aerosols 
 Metered dose 
inhaler with or 
without integral 
spacer. 
Inexpensive 
 
 Difficult for 
patients to 
coordinate 
actuation and 
inspiration. 
 Inefficient drug 
delivery as a 
result of poor 
technique. 
 Some still 
contain CFCS.* 
 Local side 
effects because 
of drug 
deposition in the 
mouth. 
 
 
 
 Breath actuated 
metered dose 
inhaler. 
 Small volume 
spacer available 
for some devices. 
 
 No requirement 
for 
coordination. 
 Portable. 
 Simple to use 
with minimal 
effort. 
 
 
 Click on 
actuation may 
be off-putting. 
 Some devices 
may be 
expensive. 
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1.8 Pharmaceutical care 
Pharmaceutical care was originated from a term, defined in 1975 by Mikeal et al[31] as a subset 
of medical care. After that, the concept developed, according to the environment of the changing 
community and its demands on the pharmacy. Pharmaceutical care includes the drug needs for a 
given patient, which involves providing the services needed for safe and effective therapy and  
the required drugs [2,27]. The role of the pharmacist which was traditionally restricted to the 
Dry powder 
 Turbohaler. 
 Clickhaler. 
 Accuhaler. 
 
 
 
 Simple to use 
with minimal 
inspiratory 
effort. 
 Indicator of 
number of doses 
remaining. 
 Portable. 
 Robust devices. 
 Devices may 
be expensive. 
 Not 
refillable. 
 
 Diskhaler. 
 Spinhaler. 
 Rotahaler. 
 Aerochamber
. 
 Difficult for 
some patients 
to load or 
prime. 
 Requirement 
to protect the 
capsules 
against 
extremes of 
temperatures 
and 
humidity. 
 
Nebuliser  Compressor 
 Simple to use. 
 Deliver high 
doses. 
 Over reliance 
may be a 
problem. 
 Inefficient 
drug 
delivery. 
 Steroids 
require a 
mouthpiece 
rather than a 
mask. 
 Expensive. 
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preparation, dispensing and selling of medicines expanded by this form of practice to enjoin the 
pharmacist, in addition to dispensing of medicines, and achieving specific therapeutic outcomes, 
also he assume the responsible of improving the quality of patients outcomes [19]. 
Since then, pharmacists have worked to develop pharmaceutical care practices. There are several  
published literature that show many examples of these practices, suggesting that the participation 
of a pharmacist in the evaluation of patients  drug therapy regimen improves outcomes [70, 71] 
Although, pharmaceutical care which involves the detection, prevention, and solution of drug-
related problems has proved beneficial in diseases such as asthma and cancer [72, 73], also it can  
provide beneficial with all kinds of diseases on any type of drug therapy, thereby; meeting the 
drug related needs of individuals and communities [19]. This is because most patients are 
prescribed multiple drug regimens, there are some studies shows multiple drug regimens such as 
study done by Perkin et al. that show the complex of drug regimens are usually associated with 
noncompliance especially after discharge from hospital [74]. Also the study that done Strand et 
al. revealed that pharmacists may resolve this problem by encouraging patients compliance and 
consequently improving treatment outcomes by engaging the patient in pharmaceutical care 
activities such as monitoring, counseling, resolving drug related problems [75]. 
 
The main objectives of pharmaceutical care is to solve medication problems and it also helps to 
achieve positive clinical outcomes and optimize the health related quality of life of the patient 
within realistic expenditure [76]. Medication errors increase the cost of health care; account for 
higher utilization of hospitals, nursing homes, and physician visits; and health risks for patients 
[77, 78]. So using the pharmaceutical care and working closely with patients and other healthcare 
professionals in designing, implementing, and monitoring a therapeutic plan to produce specific 
outcomes [79, 80].
 
The pharmacist knowledge and skills are very important to teach patients to self-manage asthma. 
These abilities include how to identify if a patient‘s asthma is controlled or uncontrolled, identify 
drug or non-drug-related issues that may be hindering a patient‘s asthma control, identify 
patients without an emergency action plan, and facilitate a plan with the patient and the physician 
to help improve the patient‘s asthma control. If pharmacists shift their focus from delivering 
information about drug therapy to integrating drug and device information into a program 
 31 
focusing on achieving asthma control then pharmacists and patients would be approaching 
asthma management from similar perspectives [81]. 
 
A study by Knoell et al [82], suggested that when pharmacists became involved in asthma care, 
improvements in symptom control and patient satisfaction were noted. In the study, patients had 
a consultation that lasted up to 60 minutes with a pharmacist had an individualized self-
management plan introduced and had at least one follow up visit. Other studies have also shown 
that patients report an increased level of satisfaction with a service which includes a pharmacist 
and that increased patient education, coupled with a comprehensive asthma health management 
program, that improves both the process of care and the treatment outcomes [83-86]. 
 
The role of pharmacist in patient's educating is to provide information about asthma medications 
and demonstrate how to use inhaled medications and peak flow meters. They can help patients 
understand their asthma management plan. In addition, Pharmacists have become more and more 
active in patient care over the past years and can demonstrate a positive impact on the outcomes 
of drug therapy in asthma patients [87,88]. 
 The aim of pharmaceutical care is to optimize drug therapy, minimize drug related problems, 
and improve self-management and quality of life of patients. The pharmacist is part of the health 
care team, and extensive communication between pharmacist, physician, and patient is necessary 
to achieve defined health outcomes.[89,90]. Since then, pharmacists have worked to develop 
pharmaceutical care practices. The participation of a pharmacist in the evaluation of patients 
drug therapy regimen improves outcomes, and many examples of these practices show such 
thing in published literature [70, 71, 91]. 
In conclusion, to achieve the clinical, economic, and humane outcomes, pharmacists need to 
apply the philosophy of pharmaceutical care by working closely with patients and other 
healthcare professionals in designing, implementing, and monitoring a therapeutic plan to 
produce specific outcomes [79, 92]. The differences between traditional dispensing and 
pharmaceutical care are list in table (5). 
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Table (5):  The Differences between traditional dispensing and pharmaceutical care 
 
Traditional drug dispensing 
 
 
Pharmaceutical care 
 
Focus on dispensing the medicine 
 
Focus on patient‘s management and 
outcomes with the drug treatment. 
 
Patient‘s education and counseling 
 
 
In addition with technical advice, the 
concentrate on technical advice pharmacist 
is training the patient to practice in everyday 
life. 
 
No monitoring of the outcomes of the drug 
treatment 
 
The pharmacist is finding methods to drug 
treatment monitor the outcomes of the drug 
treatment. 
Drug related problems will emerge if the 
patient tells about them. 
 
The pharmacist is actively and 
systematically identifying possible problems 
in drug treatment. 
No responsibility for the drug treatment The pharmacist takes responsibility that the 
desired outcomes of the drug treatment will 
be achieved. 
 
 
1.9 Problem statements 
1.9.1 Poor Asthma Control 
 
Most asthma patients in the general population are not properly controlled and this appears to be 
a worldwide problem. So Asthma management guidelines provide recommendations for the 
optimal control of asthma and asthma therapies of proven efficacy [93]. The International 
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guidelines Global initiatives for asthma (GINA guidelines) that define control of asthma as 
minimal chronic symptoms, minimal (infrequent) exacerbations, no emergency visits, minimal 
use of as needed rapid acting β2-agonists, no limitations on activities, daily peak expiratory flow 
(PEF) variation of less than 20%, near normal PEF and minimal adverse effects from 
medications [29]. 
International guidelines Global initiatives for asthma (GINA) clearly establish the importance of 
anti-inflammatory drugs and bronchodilators for optimal control of the disease. However, and 
despite the fact that the currently available therapeutic arsenal against persistent asthma is 
excellent, but many patients have poor control of the disease [29]. This is  because of the poor 
adherence to prescribed medication, particularly inhaled steroids, and partly because of the abuse 
of inhaled short-acting bronchodilators to relieve symptoms [94,95]. Furthermore, the 
improvement of the quality of care in asthma requires a comprehensive knowledge of patients 
and the management of their asthma. Therefore, some studies have reported better asthma 
control when the patients themselves felt adequately informed on asthma and when they were 
involved in the management of their disease. 
So when asthma was controlled this  leads to a significant reduction in costs, that due to 
uncontrolled disease and result from admission to hospital, use of emergency services, and 
absenteeism from school and work. Therefore, controlling the condition benefits patients in 
particular and society in general. 
1.9.2 Patient Non-Compliance: 
 
Patient's compliance with inhaled therapy leads to successful treatment outcome, this compliance 
even when they are feeling well and suffering no overt symptoms of their disease. The 
importance of regular inhaled corticosteroids should be emphasised. Also Patient education 
should distinguish between reliever, preventer and controller medication and the patient should 
be aware of inhaler technique, such as rinsing their mouth or brushing their teeth after using their 
corticosteroid inhaler in order to minimize local side-effects. 
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Pharmacists in both community and hospital practice are well placed to provide continued 
information and reinforcement of key messages to improve compliance with medication and the 
outcomes of asthma management plans. 
So asthma management guidelines recommend the appropriate drug treatment for patients based 
upon the severity of their disease. The choice of delivery device is equally important like the 
choice of therapeutic agent, because the amount of drug delivered to the lungs differs from 
device to device. Furthermore, the device choice should be easy to use and consistency of drug 
release which all have implications for patient compliance. However, patients are frequently non-
compliant with their therapy due in part to non-implementation of and non-adherence to asthma 
management guidelines by the doctors and also due to misuse of inhaler devices.                                                                                                                   
The major cause of poor asthma control is related to patient non-compliance with therapy [96]. 
The reasons for patient non-compliance with asthma therapy are complex and involve both drug-
related and non-drug-related factors. Drug related factors include a difficulty using the inhaler 
device; complicated treatment regimens; side effects of treatment; cost; the fact that people do 
not like taking drugs or that the treatment is not readily available. Other important nondrug 
related factors for patient's non-compliance include; not understanding the instructions; worrying 
about side effects; not trusting the doctor; not being supervised when taking medication so 
compliance is never checked; and anger about being ill. Finally, cultural factors such as; patients 
do not like being labeled with the disease, they may forget to take the treatment. 
1.9.3 Difficulty Using Inhalers 
The administration of inhaled medications is a fundamental component of the clinical treatment 
of patients with pulmonary disease. The use of inhalers makes it possible to selectively reach the 
lungs, this lead to increasing the concentration of the drug so reducing systemic adverse effects. 
The effectiveness of the inhaled medication depends on the formulation and the type of device 
used and also on the ability of the patient to perform the inhalation technique correctly [97]. 
The major reason for patient's noncompliance therapy is the inability to use the inhaler device 
correctly and this may impact negatively on asthma control. Therefore, theuse 
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of inhalers requires accurate completion of multiple steps to ensure effective medication 
delivery. The effectiveness of inhaler therapy depends not only on compliance, but also on the 
inhaler technique [98]. 
There are many different types of inhaler devices available to patients and they can differ in the 
way in which the inhaler dispenses the medication; whether it is passively or actively generated 
(i.e. the aerosol-generating properties which can be propellant, mechanical, or compressed air), 
Dose preparation for DPIs (dry powder inhalers), the type of formulation (e.g. solution, dry 
powder etc.).The inhalers may contain medication in a single or multi dose, disposable or 
refillable, or contain a reservoir [99]. 
The most prescribed inhaler device worldwide is pMDI (pressurized metered dose inhalers) 
although most patients cannot use it correctly.
 
 This is because pMDIs require good coordination 
of patient inspiration and inhaler activation to ensure correct inhalation and deposition of drug in 
the lung. Patients frequently fail to continuously inhale  slowly after activation of the inhaler and 
exhale fully before the inhalation [68].     
There are different problems when using the pMDI included: patients had difficulty to co-
ordinate aerosol release with inspiration (54% patients); they stop inhalation upon release of the 
aerosol (24% patients) and breathe through the nose whilst actuating the inhaler in the mouth 
(12% patients) [100]. For example in 1982, 633 patients (54%) attending hospital during a 3 
month period were found to be unable to use a pMDI efficiently after reading the patient 
information leaflet for the inhaler or having the correct use of a pMDI demonstrated to them 
[100]. And  By 2000, only 21% of patients were able to use a pMDI correctly after reading the 
package insert, and just over half of patients (52%) used a pMDI correctly after receiving 
instruction [101]. By contrast, 89% of patients were able to use a dry powder inhaler (DPI) or 
breath activated device correctly following instruction [101].                       
According to these observations the majority of asthmatic patients probably derive incomplete 
benefit from the use of pMDIs. Although training apparently results in a more efficient use of the 
canisters, training sessions must be repeated, and the results checked at regular intervals by a 
member of the medical staff.In patients who repeatedly fail to achieve a correct inhalation 
technique, the drug should be given using an alternative inhalation device.                            
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The improper use of pMDIs is not confined to patients. Both nurses and physicians have also 
been shown to use pMDIs incorrectly despite their increased awareness of the importance of a 
correct inhalation technique in the use of the pMDI[102].  
There are the Dry powder inhalers (DPIs) that have several advantages over pMDIs; they are 
breath activated (avoiding coordination difficulties between actuation and inhalation), easy and 
convenient to use, and environmentally friendly [103]. 
1.10 Thesis Objectives 
1.10.1 Aim of the study 
The main aim of the study was to investigate the clinical and humanistic impact of 
pharmaceutical care intervention led by clinical pharmacist in adult patients with asthma. 
1.10.2 Objectives of the study 
 
1- To assess the impact of pharmacist intervention on disease control among asthmatic patients 
as measured by Asthma Control Test (ACT). 
2- To assess the impact of pharmaceutical care intervention on patient knowledge about their 
disease and its management. 
3- To assess the impact of the pharmaceutical care on patient's adherence to asthma therapy 
measured by Morisky adherence questionnaire. 
4- To assess the Inhalation Techniques and determine the risk factor for poor techniques. 
1.11Research Questions 
1. Does patient with asthma have good compliance with his inhaled therapy? 
2. Does patient with asthma improve his inhalation technique? 
3. Can pharmaceutical care be successful in improving asthma control, medication adherence and 
patient's knowledge? 
 
 37 
 
 
 
 
 
 
 
 
 
Literature review 
 
 
 
 
 
 
 
 
 38 
Chapter two 
Literature review 
 
As asthma is associated with an enormous social, psychological, and economic burden, various 
patient education programs have been developed to improve outcomes, including quality of life.  
A number of randomized controlled trials showed the effectiveness of community pharmacy-
based interventions on lung function, health related quality of life, and self-management in 
asthma patients. In this section, I am going to discuss a number of these trials which showed the 
significant positive impact of pharmaceutical care services for asthma patients. 
 
2.1 Pharmaceutical Care Services for Asthma Patients: A Controlled Intervention Study. 
 
In the Hamburg city, a 26 of intervention pharmacy and 22 of control pharmacy were agreed to 
participate in the study. The mission of intervention pharmacies were asked to deliver a 
pharmaceutical care in one to one meeting in counseling room. 
In this study, the authors evaluated the effectiveness of community pharmacy-based 
interventions on lung function, health-related quality of life, and self-management in asthma 
patients in a 12 month controlled intervention study in 26 intervention and 22 control 
pharmacies. According to this, patients (ages 18-65) with mild to severe asthma attending the 
pharmacies were allocated to the intervention (n = 161) or control group (n = 81), respectively. 
Intervention patients were educated on their disease, pharmacotherapy, and self-management; 
inhalation technique was assessed and, if necessary, corrected. As a result of pharmaceutical care 
a significant improvement in inhalation technique, peak flow, self-efficacy, and knowledge were 
observed [104]. 
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2.2 Assessment of a community pharmacy-based program for patients with asthma. 
In Malta,a 11 patients of intervention group were received verbal counseling, an information 
leaflet, an educational video, but a 11 patients of control group received a routine dispensing 
services. 
The intervention patients have a greater improvement in inhaler technique, medication 
knowledge, and quality of life at 12 months [105].  Post intervention follow up a Maltese study 
reported that a community pharmacy based asthma education and monitoring program had a 
positive impact on quality of life, inhaler technique, peak expiratory flow, compliance with 
therapy and number of hospitalizations at 4, 8, and 12 months [106].Health-related quality of life 
of the intervention patients improved at 12 months (p=0.044). In the same time period, PEF 
significantly decreased in control patients compared with intervention patients (p=0.009) 
whereas inhaler technique improved in the intervention group (p=0.021). There were 
significantly fewer self-reported hospitalizations in intervention patients.  
2.3 Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the 
community. 
 
In Australia, a randomized controlled study was conducted to assess the impact of a community 
pharmacy asthma care program on asthma control, clinical and humanistic outcomes. In the 
study about 191 and 205 patients were recruited in the intervention and control groups 
respectively. 
The outcomes measures were recorded at baseline and 6 months later. The findings of the study 
reported a significant improvements in the intervention group compared to the control group in 
relation to asthma control, adherence to preventer medication, quality of life, asthma knowledge 
and inhaler technique [109]. 
2.4 Developing and marketing a community pharmacy-based asthma management program. 
 
This study the program was developed by an independent community pharmacy. In the study, 
patients who completed one year in the program had a 77% decrease in hospitalization and 78% 
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decrease in emergency department visits compared with year prior to enrollment in the program. 
Accordingly, that program proved to be an effective, practical, and profitable addition to the 
portfolio of services offered by the pharmacy[108]. 
2.5 Community pharmacy-based pharmaceutical care for asthma patients. 
 
This study evaluate the effectiveness of pharmaceutical care with regard to clinical, humanistic, 
and economic outcomes in adults with asthma, this include an intervention study that conducted 
over 12 months, and the study included 39 community pharmacies, 84 primary care physicians, 
and 183 patients aged from 18-65 years and diagnosed with asthma; and al the results compared 
with those of control group. 
The results of the study showed that a significant improvement for all humanistic outcomes such 
as; asthma specific quality of life, self-efficacy, knowledge, medication adherence. 
In addition, asthma severity, self-reported symptoms, peak expiratory flow, and patient's 
inhalation technique were improved. Also, the study shows that pharmaceutical care for people 
with asthma has a positive impact on humanistic outcomes [107].  
2.6Significanceof the study 
 
Pharmaceutical care practice is intended to meet a need in the health care system that has arisen 
due to the increase in complexity of drug therapy and the significant of drug related mortality 
and morbidity associated with drug use. Therefore, the introduction of pharmaceutical care is 
required to aid in the resolution of medication related problems. So in this study we implemented 
and assessed hospital based pharmaceutical care services for patients with asthma in Al-
Makassed hospital – Jerusalem. 
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Chapter three 
Methodology 
3.1 Demography of the study area: 
 
Al-Makassed Islamic Charitable Society was officially established in 1956. It is a Palestinian 
non-profit, nongovernmental organization that provides diversified humanitarian services in the 
In 1964, the society began construction of the hospital on the Mount of Olives in Jerusalem. The 
hospital was officially inaugurated in 1968 as a small community hospital with several 
departments and a limited number of beds. 
 Al-Makassed Hospital today is the leading medical center in Palestine, providing secondary and 
tertiary health services for all citizens of Palestine. Now, Al-Makassed Hospital has 250 beds and 
is staffed by 750 employees. 
3.2Study Design 
This is a prospective randomized control study that was conducted in outpatient clinic at Al-
Makassed hospital after an approval and permission of Al-Makassed hospital with supervisor Dr. 
Amro Alastal. This study was a 12 month randomized controlled trial during the period from 
September 2014 to September 2015; the patients were randomized using computer generated 
random numbers. 
Targeted patients who are 18 years of age or over. With persistent asthma and who were 
followed up by their physicians and receiving treatment with an inhaled corticosteroid (alone or 
in combination with a long acting bronchodilator) as maintenance treatment for the control of 
asthma. Patients gave their informed consent to participate in the study. 
3.3. Sample size 
 
The sample size was estimated using the Raosoft sample size calculator [110]. Minimum sample 
sizes for different potential analyses were calculated using the methods described by Cohen 
[111]. 
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Simple randomization was used to allocate the patients either to controlled or intervention group 
based mainly on gender, asthma severity and asthma duration. 
A sample of 243 patients agreed to participant in this study, at baseline the number of patients 
who participated in the study were 106 and 137 patients in the control and intervention groups, 
respectively. At 6 months, 101 and 122 patients were in the control and intervention groups, 
respectively. Finally, at 12 month 90 and 102 patients were in the control and intervention 
groups respectively as shown in Figure(5). 
3.4 Data Collection 
 
During clinic visits, the well trained clinical pharmacist administered the standard 
questionnaires. Patients were evaluated according to FEV1,symptoms, clinical data and disease 
characteristics by the physician. Age, sex, weight, height, body mass index (BMI), education, 
smoking status, social insurance coverage, duration of asthma, concomitant diseases, asthma-
associated diseases (rhinitis, sinusitis, gastroesophageal reflux), and status of the disease in the 
last year were recorded. Patients were asked questions pertaining to anti-asthma medications 
they had received for asthma in the last 12 months prior to inclusion in the study. The patients 
were asked if they have been prescribed or given Peak Flow Meter (PFM) and Asthma Action 
Plan (AAP) tools, whether they found them useful, and what problems they perceived with their 
use. 
Pharmacists evaluated patient's inhaler technique, using specific check lists for each study 
inhaler device type, both before and after providing training in inhaler use. For each patient, they 
recorded the number of attempts of using the inhaler and the length of education time required 
before obtaining adequate inhaler technique. At the end of the training session, the pharmacist 
gave complete written instructions for the patient, personalized according to observed inhaler 
technique and the errors that had been identified Appendix (1). 
3.5Inclusion criteria: 
 
The inclusion criteria includes: (1)Patients had to be 18 years of age or over with a 6 month 
history of diagnosed persistent asthma and receiving treatment for at least the last 6 months with 
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inhaled (alone or in combination with a long-acting bronchodilator) as maintenance treatment for 
the control of asthma.(2) Patients in a stable condition during the previous month who had not 
required changes in maintenance treatment for asthma during this period.(3)Patients had to have 
given their informed consent to participate in the study. 
3.6 Exclusion criteria 
 
The exclusion criteria as follows: (1) Terminal stage illness with less than 6 months life 
expectancy. (2) Presence of psychological or psychiatric disorders would prevent a correct 
evaluation of the evaluation of the degree of asthma control. (3) Intravenous or oral 
corticosteroids during the previous month (4) Admission to a hospital or institution at enrollment 
as a result of asthma. (5)  Non-fulfillment of all the inclusion criteria. 
3.7 Questionnaires Data 
 
The questionnaires required for study completion included: 
1) Demographic and clinical data about the participants (Appendix2). 
2) Asthma Control Test (ACT) (Appendix 3). 
3) Medication Adherence Test (Appendix 4). 
4) Asthma Knowledge Questionnaire (Appendix5). 
5) Manual (Appendix 6). 
6) Asthma Action Plan(AAP)(Appendix7). 
3.8 Measurements 
3.8.1 Demographic and clinical data about the participants 
 
Demographic data (age, sex, and race), socioeconomic data (level of education), data on daily 
activities were recorded. Thropometric parameters; weight and height were recorded. In addition, 
clinical variables included a history of smoking, medication use, GP(general practitioner) visits 
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and number of admissions due to asthma during the last year were also obtained in a customized 
questionnaire. Appendix (2). 
3.8. 2 Asthma Control Test (ACT) 
 
Asthma control test is a self-administered 5 item questionnaire developed for assessing asthma 
control level [112]. It evaluates the most recent 4 week time period; each item is scored between 
1 and 5, with the total score ranging from 5 to 25. An ACT score of 25 indicates that asthma is 
―controlled,‖ whereas a score between 20 and 24 shows partially controlled asthma and a score 
of <20 indicates ―uncontrolled‖ asthma. Thus, asthmatic patients were classified as follows:  
patients with a score of 25 were considered as totally controlled; those with a score of 20-24  
were considered as partially controlled and those with a score of ≤ 19 as uncontrolled asthmatics.  
Then, the totally controlled and partially controlled patients were regrouped as controlled 
patients (ACT>19) and others were included in the uncontrolled group. 
In the original validation of the ACT, the internal consistency of the questionnaire was good 
(Cronbach‘s a coefficient = 0.84) [113], and satisfactory internal consistency (Cronbach‘s a > 
0.80) has been reported in other published validation studies from other countries [111, 114, 115] 
including for an Arabic version of the ACT evaluated in Lebanon and Saudi Arabia (Cronbach‘s 
a = 0.92) [116], that is considered as clinically important for (Asthma Control Questionnaire) 
ACQ is 0.5 on the 7-point scale. 
A pilot study was done on 10 patients from Al-Makassed hospital. The Cronbach's Alpha is 0.79 
that indicates a good internal consistency and reliability and suitability for our study, Appendix 
(3). 
3.8. 3Medication Adherence Test 
 
The Morisky medication adherence scale is a commonly used adherence screening tool. It is 
composed of four yes or no questions about past medication use patterns and is thus quick and 
simple to use during drug history interviews [17]. 
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In 1986, Dr.Morisky and his colleagues published the instrument Morisky Medication Adherence 
Scale (MMAS) that was first validated in antihypertensive drugs in outpatient settings [117], 
where higher scores indicate higher levels of reported adherence. 
A pilot study was done on 10 patients from Al-Makassed hospital, The Cronbach's Alpha for all 
0.81 a good internal consistency and reliability. Appendix (4). 
3.8. 4Asthma Knowledge Questionnaire: 
 
The Original asthma knowledge questionnaire in English language was translated into Arabic 
language and termed as Arabic asthma knowledge questionnaire (AAKQ). A thorough validation 
and reliability testing was performed on AAKQ. Results revealed that the AAKQ came out with 
good reliability and consistency to evaluate the level of asthma awareness[118]. 
It is a 7 item questionnaire Designed to measure asthma knowledge of health care consumers. 
Participants answer a series of true or false questions. A higher score indicates better asthma 
knowledge. Appendix(5). 
3. 8. 5Manual: 
 
A well-organized manual book of simple written language was given to the patients in the 
intervention group prepared to assist in the education session and the patients were given a copy 
to take home with them. 
This manual contained useful information about asthma, its causes, its triggers and the best 
evidence of its management and about inhaler techniques.  
Moreover, the patients were taught about the use of written action plan to monitor their condition 
and reduce flare up, Appendix(6). 
3. 8. 6Asthma action plan (AAP) 
 
An asthma action plan is a set of written instructions that can help a person manage breathing 
problems. That way, the person doesn't have to go to the doctor or hospital all the time. A doctor 
works with a person to design a plan that works best for him or her. It can include a list of what 
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triggers the person's symptoms and how to avoid these triggers, a list of symptoms to watch for 
and what to do if they happen, and the names and doses of medications the person needs and 
when to use them. It may also include information on what to do in an emergency. Appendix(7). 
3.9.1 Control patients 
 
Control patients received usual hospital outpatient care from medical and nursing staff, but did 
not receive the structured intervention by the clinical pharmacist as intervened patients. 
During clinical visits, the patient completed several questionnaires that served as baseline 
measures of self-reported asthma related quality of life, perceived control of asthma, and asthma 
knowledge. The pharmacist was recorded the patient‘s demographic details, asthma history, 
asthma severity, medication profile, medication adherence, and their use of health care services 
over the preceding12 months.  
During the study period, the control patients received usual care (no pharmaceutical care 
intervention).  
3.9.2Intervention patients 
 
Intervention patients were educated individually by the clinical pharmacist  on asthma, their 
prescribed medication, the importance of adherence, inhaler technique (written information  were  
provided) and the management of asthma symptoms. The clinical pharmacist ensured that the 
patient know the indications, side effects and when to use the rescue and maintenance 
medication. 
The pharmacist demonstrated inhaler techniques and then asked the patients to carry out the 
techniques to ensure that they fully understand how to perform them. 
At each outpatient clinic visit (every 6 months arranged by the hospital consultant), intervention 
group patients received education on asthma and its treatment from the clinical pharmacist. In 
addition, follow up telephone calls each 3 months by the clinical pharmacist to reinforce the 
education and motivate the patients to achieve their goals were made at 6 and 12 months, i.e. 
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between outpatient clinic appointments. At each visit all intervention patients were provided with 
written action plan, written medication lists and their uses, and asthma manual book. 
 
4. Data Analysis 
 
Data was collected and analyzed by the computer software Statistical Package for Social 
Sciences Personal Computer (SPSSPC) version 22, Chi-square statistic was used to test for 
independency of the distribution of both controlled and uncontrolled asthma among the various 
categories of study variables. The level of significance set at P-value 0.05 or less. Results were 
presented and discussed in tables, bar graphs and computed in percentages. 
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Chapter four  
4. Results 
4.1 Sociodemographic data: 
 
 The number of patients at baseline was 106 and 137 patients in the control and intervention 
groups, respectively. At 6 months, 101 and 122 patients were in the control and intervention 
groups, respectively. Finally, at 12 month 90 and 102 patients were in the control and 
intervention groups, respectively. During the study period 35 patients of the intervention group 
and 16 of the control dropped out. In the intervention group, 3 patients died and 9 patients 
refused to continue, 10 could not complete the study, and others transferred to another clinic for 
follow-up. In the control group, 3 patients died,8 could not complete the study and others 
transfered to another clinic. As shown in figure (5). 
In the control group, the study population enrolled was 41(38.6%)males and 65(61.3%)females, 
while those in the intervention group were 60 (43.7%) males and 77 (56.2%) females and the 
distribution of patients according to their age in the control group was 39 (36.7%) patients  (18-
40 years), 44 (41.5%) patients (41-60 years), 23 (21.6%) patients were (>60 years), and that of 
the intervention group was 58 (42.3%), 44 (32.1%),35 (25.5%) patients respectively. 
The data was also evaluated smoking habits. Results have shown that the intervention group had 
highest percentage69 (50.3%) than control group 61(57.5%). Also, using drugs or combinations 
of drugs are used to control asthma or improve compliance in asthmatic patients. In our study, 
nearly 33 (24%) of asthmatic patients in intervention were using Ventolin and 29(27.3%) in 
control group. Whereas 28(20.4%) and 22(20.7%) were using Symbicortin intervention and 
control group consequently. And the least uses was the combination of Ventolin+ Spiriva around 
2(1.4%)in intervention and 2(1.8%)control group. 
The health status of control and intervention groups ranged from good to very good, 41 (29.9%), 
65(47.4%)in intervention group and 36(33.9%), 56 (52.8%) patients in control group. As shown 
in table (6). In general, at baseline none of the parameters evaluated showed a significant 
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difference between the two groups meaning that the control and intervention groups were similar 
at study initiation. 
Table (6): Sociodemographic data 
Characteristics 
Control group n(%) 
(n=106) 
Intervention group n(%) 
(n=137) 
 
P-value* 
Age 
  
0.319 
18-40 39(36.7%) 58(42.3%)  
41-60 44(41.5%) 44(32.1%)  
>60 23(21.6%) 35(25.5%)  
   
 
Sex 
  
0.422 
Male 41(38.6%) 60(43.7%)  
Female 65(61.3%) 77(56.2%)  
   
 
Social status 
  
0.078 
Married 9(8.4%) 21(15.3%)  
Unmarried 92(86.7%) 103(75.1%)  
Otherwise 5(4.7%) 13(9.4%)  
   
 
Educational status 
  
0.820 
Primary 2(1.8%) 5(3.6%)  
Preparatory 16(15%) 23(16.7%)  
Secondary 45(42.4%) 51(37.2%)  
College 21(19.8%) 25(18.2%)  
University 22(20.7%) 33(24%)  
   
 
Employment status 
  
0.793 
Government employee 30(28.3%) 34(24.8%)  
House wife 51(48.1%) 61(44.5%)  
Retired 12(11.3%) 18(13.1%)  
Self-employed 7(6.6%) 13(9.4%)  
Student 6(5.6%) 11(8%)  
   
 
Health insurance 
  
0.860 
Government 70(66%) 95(69.3%)  
Special 23(21.6%) 27(19.7%)  
No insurance 13(12.2%) 15(10.9%)  
   
 
Average income 
  
0.634 
<2000-2500 17(16%) 17(12.4%)  
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2500-4000 63(59.4%) 81(59.1%)  
>4000 26(24.5%) 39(28.4%)  
  
 
 
 
Smoking status 
  
0.896 
Smoker 61(57.5%) 69(50.3%)  
Non-smoker 33(31.3%) 45(32.8%)  
Ex-smoker 12(11.2%) 23(16.7%)  
   
 
Drug uses 
  
0.806 
Ventolin 29(27.3%) 33(24%)  
Symbicort 22(20.7%) 28(20.4%)  
Seretide 13(12.2%) 18(13.1%)  
Aerovent 5(4.7%) 2(1.4%)  
Ventolin+Symbicort 17(16%) 22(16%)  
Ventolin+Seretide 15(14.1%) 26(18.9%)  
Ventolin+Aerovent 3(2.8%) 6(4.3%)  
Ventolin+Spiriva 2(1.8%) 2(1.4%)  
   
 
Health status 
  
0.255 
Excellent(90-100%) 8(7.5%) 12(8.7%)  
Very good (80-90%) 56(52.8%) 65(47.4%)  
Good(60-70%) 36(33.9%) 41(29.9%)  
Little(<50) 4(3.7%) 16(11.6%)  
Acceptable(50%) 2(1.8%) 3(2.1%)  
Mean (SD) of FEV1%VC 71.5(15.1) 70.1(13.2)  
 *cross tab,Chi-Square Test 
4.2 Knowledge about medications and disease management: 
The patients had fair knowledge about their medications and disease management at baseline, as 
measured by the asthma knowledge questionnaire. Patient knowledge in the intervention group 
were higher at 6 and 12 months as shown in curve (1), and the percentage of intervention 
patients who answered correct answers were increased from baseline to 12 month, about 88% of 
intervention patients answered question one in 12 month compared with baseline about (50%), 
and about (40%) in both baseline and 12 month in control group. And at 12 month about (90%, 
50%, 50%, 77%, 70%, 80%) of patients in intervention group answered question (2, 3, 4, 5, 6, 
7)respectively, compared to baseline, but in the control group, the percentage of patients who 
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answered correct answer sat 12 month were (40%, 70%, 30%, 30%, 60%, 45%, 77%) of 
questions (2, 3, 4, 5, 6, 7)respectively, compared to baseline as shown in table (7). 
 
Curve (1): Asthma knowledge test in control and intervention group. 
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Table (7): The percentages of patients who answered correctly in the intervention and 
control groups at 0, 6, 12 month. 
 
 
 
 
Question Group 
 
0 
month 
(%) true 
6 
month 
(%) true 
12 
month 
(%) true 
People who suffer from asthma, they should 
avoid exercise because breathing becomes 
more difficult during  any kind of physical 
exertion 
Intervention 
 
50% 90% 88% 
Control 
 
40% 60% 40% 
Asthma attack does not require immediate 
attention 
Intervention 
 
50% 89% 90% 
Control 
 
30% 73% 70% 
It can be fatal asthma. Intervention 
 
32% 39% 50% 
Control 
 
12% 32% 30% 
Asthma attack occur suddenly, without 
warning 
Intervention 
 
48% 52% 50% 
Control 
 
24% 22% 30% 
There are many medications to control asthma, 
depending on the severity of the disease. 
Intervention 
 
58% 70% 77% 
Control 
 
40% 55% 60% 
The presence of different irritants cause 
asthma incidence 
Intervention 
 
46% 50% 70% 
Control 
 
32% 49% 45% 
There is no cure for asthma. 
 
Intervention 
 
20% 63% 80% 
Control 
 
15% 50% 77% 
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4.3 Adherence to prescribed medications: 
An improvement in adherence can be directly beneficial to a patient‘s clinical condition, and 
medication counseling contributes to improved medication adherence to prescribed regimens. 
Adherence to medications during the course of the study, at baseline the results show that the 
patients in the intervention group have a same adherence to medication compared to control 
group5(3.64%), 6(5.6%)respectively, with no significant improvement p value= 0.736.  
 
At 6 month, the percentage of adherence to non-adherence medication in intervention group 
were18(14.7%) and 25(20.4%), compared to control group, about 4(3.9%) were adherent and 
46(45.5%) were non-adherent to medications with a p value = 0.0003. 
 
At 12 month the adherence to medication about 10(9.8%), and non-adherence about 30(29.4%) 
in intervention group compared to control group with 3(3.3%) were adherent and 42(46.6%) 
were non-adherent to medication in intervention group and the p value was 0.021.As shown in 
table (8). 
Table (8): Medication adherence test 
 
Medication adherence test 
Control 
group 
(n,%) 
Intervention 
group 
(n,%) 
P –
value* 
 
Baseline(0M) 
 
(Control=106) 
(Intervention=137) 
 
High adherence (0) 
 
Moderate adherence (1-2) 
 
Non-adherence(3-4) 
 
 
6(5.6%) 
 
53(50%) 
 
47(44.3%) 
 
5(3.64%) 
 
72(52.55%) 
 
60(43.79%) 
 
 
 
0.736 
 
6  month 
 
(Control=101) 
(Intervention=122) 
 
 
High adherence (0) 
 
Moderate adherence (1-2) 
 
Non-adherence(3-4) 
 
 
4(3.9%) 
 
51(50.4%) 
 
46(45.5%) 
 
18(14.7%) 
 
79(64.7%) 
 
25(20.4%) 
 
 
 
0.0003 
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12 month 
 
(Control=90) 
(Intervention=102) 
 
 
High adherence (0) 
 
Moderate adherence (1-2) 
 
Non-adherence(3-4) 
 
 
3(3.3%) 
 
45(50%) 
 
42(46.6%) 
 
10(9.8%) 
 
62(60.7%) 
 
30(29.4%) 
 
 
 
0.021 
*Chi-Square Test  
 
4.4 Asthma control test: 
 
In this study, the intervention had significantly increased the ACT after 6 months compared with 
usual care, the proportion of the complete asthma control is 19(15.5%) and 5(4.9%) in 
intervention and control groups, respectively with p-value =0.002 but the proportion of the 
controlled asthma was decreased at the 12 months about 9(8.8%) in intervention group and 
7(7.7%) in control group, with non-significant p value = 0.077. As shown in table (9). 
 
Table (9): Asthma control test 
 Asthma control test 
Control group 
(n, %) 
Intervention 
group 
(n, %) 
P –
value* 
 
Baseline(0M) 
 
(Control=106) 
(Intervention=137) 
 
Complete control(20-25) 
Partial control(15-19) 
Bad control(<15) 
 
7(6.6%) 
37(34.9%) 
62(58.4%) 
 
8(5.8%) 
46(33.5%) 
83(60.5%) 
 
 
0.936 
 
 
6  month 
 
(Control=101) 
(Intervention=122) 
 
 
Complete control(20-25) 
Partial control(15-19) 
Bad control(<15) 
 
5(4.9%) 
36(35.6%) 
59(58.4%) 
 
19(15.5%) 
57(46.7%) 
46(37.7%) 
 
 
0.002 
 
 
12 month 
 
(Control=90) 
(Intervention=102) 
 
 
Complete control(20-25) 
Partial control(15-19) 
Bad control(<15) 
 
7(7.7%) 
35(38.8%) 
48(53.3%) 
 
9(8.8%) 
55(53.9%) 
38(37.2%) 
 
 
0.077 
 
*Chi-Square Test 
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4.5 Asthma inhaler technique: 
 
At the baseline enrollment, there was no significant difference and the proportion of patients who 
demonstrated appropriate inhaler technique (score=7-10) was 37(34.9%)in control group and 
49(35.7%) in intervention group, with (p value =0.736) between both groups. At 6 month the 
proportion of patients who demonstrated appropriate inhaler technique (score=7-10) was 
31(30.6%)in control group and 113(92.6%) in intervention group with a significant p-
value=0.0001 but at 12 month the proportion of patients who demonstrated appropriate inhaler 
technique was slightly decreased about 88(86.2%) in intervention group and 32(35.5%) in 
control group, with p-value =0.021.As shown in table (10). 
 
Table (10): Asthma inhaler technique 
*Chi-Square Test  
 
 
 
 
Asthma inhaler 
technique 
Control group 
(n,%) 
Intervention 
group 
(n,%) 
*P –value 
 
Baseline(0M) 
 
(Control=106) 
(Intervention=137) 
 
 
Appropriate(7-10) 
Inappropriate(1-6) 
 
37(34.9%) 
69(65%) 
 
49(35.7%) 
88(64.2%) 
 
 
0.736 
 
 
6  month 
 
(Control=101) 
(Intervention=122) 
 
 
Appropriate(7-10) 
Inappropriate(1-6) 
 
31(30.6%) 
70(69.3%) 
 
113(92.6%) 
9(7.3%) 
 
 
0.0001 
 
 
12 month 
 
(Control=90) 
(Intervention=102) 
 
Appropriate(7-10) 
Inappropriate(1-6) 
 
32(35.5%) 
58(64.4%) 
 
88(86.2%) 
14(13.7%) 
 
0.021 
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4.6 Asthma severity: 
 
In this study at the baseline enrollment, there was no significant difference in continued asthma 
severity values between both groups about 15(14.1%) in control group and 22(16%) in intervention 
group, with (p value=0.227). But at 12 month, there was a highly significant improvement in 
continued asthma severity values about 3(2.94%) in intervention group and 10(11.11%)in control 
groups with p-value=0.001.As shown in table (11). 
 
Table (11): Asthma severity test 
 Asthma severity 
Control group 
(n,%) 
Intervention group 
(n,%) 
P –value* 
 
Baseline(0M) 
 
(Control=106) 
(Intervention=137) 
 
Intermittent 
light continue 
moderate continue 
severe continue 
 
 
19(17.9%) 
37(34.9%) 
35(33%) 
15(14.1%) 
 
14(10.2%) 
43(31.3%) 
58(42.3%) 
22(16%) 
 
 
0.227 
 
6  month 
 
(Control=101) 
(Intervention=122) 
 
 
Intermittent 
light continue 
Moderate continue 
Severe continue 
 
 
17(16.8%) 
36(35.6%) 
40(39.6%) 
8(7.9%) 
 
 
16(13.1%) 
61(50%) 
39(31.9%) 
6(4.9%) 
 
0.137 
 
 
12 month 
 
(Control=90) 
(Intervention=102) 
 
 
Intermittent 
light continue 
Moderate continue 
Severe continue 
 
 
12(13.33%) 
31(34.44%) 
37(41.11%) 
10(11.11%) 
 
20(19.6%) 
56(54.9%) 
23(22.54%) 
3(2.94%) 
 
0.001 
 
*Chi-Square Test 
4.7 Hospital visit: 
 
At the 12-month follow-up, patients in the intervention group had a significant reduction in both 
hospital admissions (15 vs 36) visits with P- value =0.03 and ED visits (29 vs 58) visits with P- 
value =0.01 and 0.03 respectively. There was no significant differences in GP visits between 
control and intervention group (P =0.11). The overall length of hospital stay was significantly 
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lower in the intervention group (49 days) while in control group around (124 days) as shown in 
table (12).       
 
Table (12): Hospital admission, emergency department (ED) visits and general practitioner 
(GP) visits during the 12-month follow-up period. 
Variable Control (90) Intervention (102) P-Value 
 
Gp Visit 
 
 
166 
 
159 
 
0.11
†
 
 
ED Visit 
 
 
58 
 
29 
 
0.01
†
 
 
Hospital admission 
 
 
36 
 
15 
 
0.03
†
 
 
Hospital Days 
 
 
124 
 
49 
 
0.001* 
†: χ2 test. * Mann–Whitney test, ED: Emergency Department  
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Chapter five 
5.1 Discussion  
 
 This randomized controlled clinical trial was conducted in outpatient clinic at Al-Makassed 
hospital after an approval and permission of Al-Makassed hospital with supervisor Dr. Amro 
Alastal. This study was a 12 month randomized controlled trial during the period from 
September 2014 to September2015 and the targeted patients who are 18 years of age or over with 
persistent asthma and who were followed up by their physicians and receiving treatment with an 
inhaled corticosteroid (alone or in combination with a long acting bronchodilator) as 
maintenance treatment for the control of asthma. Patients were divided into the intervention 
group who received pharmaceutical care through asthma education, medication counseling and 
the control group who were not provided any pharmaceutical care.  
This thesis reports is the first randomized controlled trial assessing the impact of a community 
pharmacist intervention promoting optimal asthma medication use on asthma control in Palestine 
especially in Al -Makassed hospital. 
Intervention improved both the inhalation technique and medication adherence, which are both a 
key stone for successful asthma management. 
The intervention also improved asthma control of insufficiently controlled patients and, for the 
entire study group, reduced the use of reliever medication and the frequency of using it. 
Although a correct use of inhaler device is the essential way for a medicine to arrive at its target 
organ. There is evidence that poor inhaler technique is associated with poor asthma control [119]. 
In the baseline of this study, many patients in control and intervention groups (score less than 7) 
about 69 (65%)and 88 (64.2%) respectively did not use their inhaler devices correctly, and there 
was no significant difference (p value 0.736) between two groups so the pharmaceutical care by  
pharmacists could play an important role in this area, by teaching the patients how to use their 
inhaler devices properly and regularly checking the technique during the course of treatment 
(especially when therapeutic goals are not met), this improvement was showed in 6 month the 
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proportion of patients who demonstrated appropriate inhaler technique (score= 7-10), it was 31 
(30.6%)in control group and 113 (92.6%) in intervention group with a significant p-
value=0.0001 but at 12 month the proportion of patients who demonstrated appropriate inhaler 
technique was slightly decreased with p-value =0.021. The reason for this, when patients become 
better than before the compliance decrease.  
 
Thus, proper technique skills must be demonstrated to the patients, and should be checked in 
every visit to reinforce good technique. Many studies have shown that education could have a 
large impact on the percentage of patients who use their inhaler correctly [120-122]. 
 
Besides inhalation techniques, asthma management also depends on the patient's adherence to 
their medications. Several studies have shown that adherence to asthma therapy is low mainly 
with inhaled corticosteroids[123, 124]. 
 
The importance of patient education about his inhaled medications is a way to improve 
adherence, it should be emphasized that the medication profile such as type and daily dose of 
asthma medication, should be taken in a good and correct manner to improve patient‘s adherence 
to their medication.  
 
In the present study, at baseline the results showed that the patients in the intervention group and 
control group were the same and has no significant difference p value=0.736,then improvements 
in symptom control seen in the intervention group rather than control group. This proves the 
importance of education on adherence. 
 
The patients had fair knowledge about their medication and disease management at baseline, as 
measured by the asthma knowledge questionnaire. There was no significant difference between 
the intervention and control groups (P = 0.413). Overall, the percentages of patients who 
answered a true answer at 6 and 12 month increased compared to baseline. 
 
As such, the intervention group showed a significant improvement during the follow up with 
regard to knowledge about asthma. This study points out the effective role that a pharmacist can 
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play in providing patients with deeper insights into their disease and drug therapy through patient 
counseling. 
 
The improved knowledge is a good base for safe and rational drug use and will help patients to 
gain confidence in appropriate self-management of asthma, different studies have shown that 
patients who have increased knowledge about their disease and drug therapy have better control 
asthma, and our results were in line with other previous studies [125, 126]. 
 
The use of ACT or in clinical pharmacy could be an efficient tool to improve asthma control, 
whereby the pharmacist's advice could depends on the patients ACT score. 
An ACT score of 20-25 indicates good or complete asthma control, so these patients need a little 
specific advice. For patients who have an ACT score of 15-19, indicating partial controlled 
asthma, the pharmacist could improve the patient's inhalation technique and point the patient at 
the importance of adherence to the maintenance treatment. In case of an ACT score below 15, 
this mean that the patient has bad control to asthma and needs more counseling and care because 
there is a high risk for severe asthma attacks. 
 
Asthma control test in our study showed that the intervention had significantly increased the 
ACT after 6 months compared with usual care with p-value =0.002 but the proportion of the 
controlled asthma was decreased at the 12 months with non-significant p value = 0.077.It seems 
likely that these clinical improvements result from the more appropriate use of the asthma 
controller medication. 
Likewise the pharmaceutical care and asthma management in this study decreasedat the 12-
month follow-up, patients in the intervention group had a significant reduction in both hospital 
admissions (15 vs 36) visits with P- value =0.03 and ED visits (29 vs 58) visits with P- value 
=0.01 and 0.03 respectively. There was no significant differences in GP visits between control 
and intervention group (P =0.11). The overall length of hospital stay was significantly lower in 
the intervention group (49 days) while in control group around (124 days). 
Different studies have reported a reduction in emergency visits and hospital admissions as a 
result of educational and self-management interventions. And our results were in line with other 
previous studies [127. 128], as in inhaler technique the proportion of patients who demonstrated 
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appropriate at 12 months was slightly decreased with p-value =0.021. The reason for this, when 
patients become better than before the compliance decrease. 
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Chapter six 
 
Conclusions and Future directions 
6.1Conclusions 
 
The aim of the asthma management is to gain and maintain control of asthma. Clinical 
pharmacists can develop clinical management plans and asthma action plans for asthma patients, 
reviewing and educating on inhaler technique as patients who know more about their disease and 
their drug therapy reach better control of their asthma are better prepared to cope with asthma 
[129].  
Patient counselingalso by a clinical pharmacists can lead to get better patient understanding of 
their disease and the role of medications in its treatment, improvement in asthma control, asthma 
knowledge and medication adherence to asthma as shown in different studies[130,131], at the 
end the asthma patients achieve the desired health outcomes. Moreover, a good professional 
rapport will be built between the pharmacist and patients. 
In addition, asthma control can be optimized if patients regularly monitor their asthma. To 
achieve this, the patient needs self-management by detection of changes in their condition, 
making timely adjustments to his asthma medications and knowing when to seek medicinal care. 
Finally, pharmacists and other health care professionals would appreciate the role of pharmacist 
in counseling and educating patients. 
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6.2 Future directions 
 
There are different studies performed in different fields related to pharmaceutical care. However, 
implementation on a large scale still appears to be lacking, despite the positive outcomes of most 
studies. 
Because many pharmacists recognize the importance of pharmaceutical care, so we expect more 
and more pharmaceutical care services by pharmacies in the future. However, in addition to 
reforming the attitude, knowledge and skills of pharmacists, there must be some remuneration 
for their provision of pharmaceutical care. And the pharmacist will be recognize that he is 
responsible for detecting, protecting and correcting drug related problems. 
Finally, pharmaceutical care should be an important part of the pharmacy profession and good 
pharmacy practice. 
 
 
 
 
 
 
 
 
 
 
 
 66 
Figure (5):Flow chart of our study: 
 
290patients approved 
243 patients agreed 
137 intervention  patients 
baseline data collection and intervention  
(first visit) 
3nd months phone call 
reinforcement 
6th months reinforce intervention and data 
collection 
(122 patient) 
3 patients die 
4 couldn't complete the questionnaires 
2 transfered to another clinic 
 
9th months phone call 
reinforcement  
12th months intervention and data 
collection 
(102 patient) 
11 transfered to another clinic 
9 refused to continue 
6 couldn'tt complete the questionnaires 
 
106 control patients 
baseline data collection 
usual care  
(first visit) 
 
6th months data collection  
usual care 
(101 patients) 
          5 couldn't complete the questionnaires 
3 transfered to another clinic 
 
12th months  data collection 
usual care 
(90 patients) 
3 patients died 
2 transfered to another clinic 
3 couldn't complete the questionnaires 
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Appendix (1): Asthma inhaler technique 
وبرلا ةيودأ ماذختسا ةينقت 
خم٠شؿ ِٓ ذوؤزٌا ٚ قبشٕزعلاا صبٙع َاذخزعا خ١ف١و هٌ شٙل٠ ْأ غ٠شٌّا ِٓ تٍـ٠   ِْٛاذخزغ٠ ٛثشٌا ِٓ ْٛٔبو٠ ٓ٠زٌا نبػشِ
.ؼ١ؾظٌا ًىشٌبث قبشٕزعلاا حضٙعأ 
 
Pressurised metered-dose inhaler: Is a pocket size, pressurized multiple-
dose inhalation delivery systems, able to deliver small, precisely measured therapeutic doses, 
greatly minimising the risk of side effects. 
or a  corticosteroid ,bronchodilator The medication in a metered dose inhaler is most commonly a
.bothcombination of  
 1ءبـغٌا خٌاصإ. 
 2. )ذعٚ ْإ( ٜٛزؾٌّا خهشع كمؾر 
 3اذ١ع ض٘ٚ ُ١مزغِ  ًىشثٚ ٍٝهلؤٍلبشٕزعلاا صبٙع نفسا. 
 4قبشٕزعلاا صبٙع ٓه اذ١وث ،فـٍث طسبخ ظفٕر. 
 5نػٚ.  ُزخ ً١ىشزٌ ٓ١زفشٌبث قلاغلاا ٚ غه ْٚد ْبٕعلأا ٓ١ث قٛثذ١ع 
 6. .خٔاٛـعا ٍٝه حذشث ًفعلأ ؾغػا ،ذلٌٛا ظفٔ ٟف ٚ ُفٌا يلاخ ِٓ ءؾجث ظفٕزٌا ٟف ءذجٌا 
 7. كّوثٚ ءؾجث ظفٕزٌا ٟف ساشّزعلاا 
 8.  حذٌّ ظفٕزٌا هغِ5  ْاٛص 
 9ُفٌا ِٓ قبشٕزعلاا صبٙع يصأ.ظفٌٕا هعبِ ذٔاٚ. 
 10قبشٕزعلاا  صبٙع ٓه اذ١وث ،فـٍث ش١فضٌا. 
 
Turbunhaler: Is a tube-shaped inhaler which has the medication inside in the 
form of a dry powder. They have a removable cover and a twisting base. The device is ‗breath-
activated‘ which means the dry powder medication is ‗sucked‘ from the device rather than ‗fired‘ 
like it is from other devices. 
Contain Pulmicort (preventer), Symbicort (combination medication), Oxis (symptom controller) 
and Bricanyl (reliever). 
 1ءبـغٌا خٌاصاٚ هف. 
 2. ٜٛزؾٌّا خهشع ِٓ كمؾر 
 3. خؼجمٌا ءاٛزٌا ٓ١ؽ ٟف ُ١مزغِ ًىشث قبشٕزعلاا صبٙع ٍٝه فبفؾٌا 
 4 فٌ.حشمٔ نّغر ٝزؽ ءاسٌٍٛ ذه  ُص خؼجمٌا 
 5. قبشٕزعلاا صبٙع ٓه اذ١وث ،فـٍث ش١فضٌا 
 6ذ١ع ُزخ ً١ىشزٌ ٖبفشٌبث  قلاغلااٚ غه ْٚد ْبٕعلأا ٓ١ث بلٛث نػ. 
 7كّوثٚ حٛمث ظفٕر. 
 8.  حذٌّ ظفٌٕا هغِ5  ْاٛص 
 9ُفٌا ِٓ قبشٕزعلاا صبٙع خٌاصإ. 
 10. قبشٕزعلااصبٙع  ٓه اذ١وث فـٍث ش١فضٌا 
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Accuhaler: Is a round plastic devices that have medication inside them in the 
form of a dry powder. The device is ‗breath-activated‘ which means the medication is sucked 
from the device rather than ‗fired‘ like in some other types of puffers.  
Contain Flixotide (preventer medication), Serevent (symptom controller medication) and 
Seretide (combination medication)  
 
 1ٜٛزؾٌّا خهشع ِٓ كمؾر. 
 2. َبٙثلإا َاذخزعبث ءبـغ ؼزفا 
 3. شمزغر ٝزؽ ماسزٌا ه٠شؾر ك٠شؿ ٓه خهشغٌا ض١ٙغر ،ب١مفأ  صبٙغٌا نفسا 
 4.  اذ١وث ،فـٍث طسبخ ظفٕرقبشٕزعلاا صبٙع ٓه 
 5. .ٟمفلأا قبشٕزعلاا ٍٝه فبفؾٌاٚ ،ذ١ع ُزخ ً١ىشزٌ  ٓ١زفشٌا ُػٚ ُفٌا ٟف ءاٚذٌا زخا خؾزف نػ 
 6كّوثٚ داشؿبث ٗ١ف ظفٕر. 
 7 حذٌّ ظفٔ زخأ.5 كئبلد 
 8ُفٌا ِٓ قبشٕزعلاا صبٙع يصا ، ظفٔ زخؤر ذٔاٚ 
 9. قبشٕزعلاا صبٙع ٓه اذ١وث ،فـٍث ش١فضٌا 
 10.  خهشع فطٛ٠ ارإ ِٓ داٛـخٌا سشو ،)ٓغؾزغِ َبه ًىشث ظ١ٌٚ( خ١فبػإ3-9 
 
 
Ellipta: Inhalation powder contains a combination of fluticasone and vilanterol. 
Fluticasone is a steroid. It prevents the release of substances in the body that cause        
inflammation. Vilanterol is a bronchodilator. It works by relaxing muscles in the 
airways to improve breathing. 
 1 ٜٛزؾٌّا خهشع ِٓ  كمؾر. 
 2. )قبشٕزعلاا صبٙع ضٙ٠ لا( حشمٔ نّغر ٝزؽ ًفعلأ ءبـغٌا ػصأ 
 3. قبشٕزعلاا صبٙع ٓه اذ١وث ،فـٍث ش١فضٌا 
 4. ً١ىشزٌ ٓ١زفشٌا ُػٚ ُفٌا ٟف ءاٚذٌا طٚشخ خؾزف نػ .ذ١ع ُزخ هوثبطؤث ءاٌٛٙا ظ١فٕر تغؾر لا 
 5.  كّوثٚ دشـِ ًىشث ظفٕزٌا 
 6. هغِ  حذٌّ ظفٕزٌا5 ْاٛص 
 7. ُفٌا ِٓ قبشٕزعلااصبٙع يصا ،ظفٌٕا هعبِ ذٔاٚ 
 8. قبشٕزعلاا صبٙع  ٓه اذ١وث ،فـٍث ش١فضٌا 
 9. ءاٚذٌا بِٕٙ طشخ٠ ٟزٌا خؾزفٌا خ١ـغزٌ ت٘ز٠ فٛع بِ سذمث ادٛوط ءبـغٌا نشؽ 
 
Autohaler: it is L-shaped plastic outer case, a metal canister inside,             and a 
lever at the top. This is an automatic device, so it automatically ‗fires‘ the medication when it 
senses you breathing in through the mouthpiece. Contain Airomir (reliever medication) and Qvar 
(preventer medication). 
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 إصاٌخ اٌغـبء . 1 
 اسفن عٙبص  الاعزٕشبق ثشىً  ِغزم١ُ ٚ٘ض ع١ذا .2 
 ادفن اٌشافوخ ٌلاهٍٝ .3 
 رٕفظ خبسط ثٍـف، ثو١ذا هٓ عٙبص الاعزٕشبق .4 
 اٌجٛق ث١ٓ الأعٕبْ دْٚ اٌوغ ٚػُ اٌشفبٖ ٌزشى١ً خزُ ع١ذ . وضع5 
 اؽزفق ثبٌٕفظ اٌٝ ِب ثوذ عّبم ٔمشح ٚثوّك.رٕفظ ثجؾء  .6 
 صٛاْ 5ِغه إٌفظ ٌّذح  .7 
 ٚأذ ِبعه إٌفظ,اصي عٙبص  الاعزٕشبق ِٓ اٌفُ .8 
 اٌضف١ش ثٍـف، ثو١ذا هٓ عٙبص الاعزٕشبق .9 
 دفن اٌشافوخ لأعفً .11 
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 atad lacinilc dna cihpargomeD :)2( xidneppA
 د٠ظأثٛ -عبِوخ اٌمذط
 وٍ١خ اٌظ١ذٌخ 
 اعزج١بْ هٓ ِشع اٌشثٛ
 
   atad lacinilc dna cihpargomeD اٌشعبء الإعبثخ هٍٝ الأعئٍخ اٌزبٌ١خ:
 
 . اٌوّش : ...............1
 . اٌٛصْ : ..............2
 . اٌـٛي : ..............3
 
 اٌغٕظ : o
 أضٝ o روش          o
 
 اٌؾبٌخ الاعزّبه١خ : o
 غ١ش رٌه o
  
 اٌّغزٜٛ اٌزوٍ١ّٟ :
 اعبعٟ
 اهذادٞ
 صبٔٛٞ
 وٍ١خ
 عبِوخ
 
 إٌّٙخ :
 ِٛكف ؽىِٟٛ
 سثخ ِٕضي
 ِزمبهذ
 هبًِ ٌؾغبثٗ اٌخبص
 ؿبٌت
 غ١ش رٌه
 
 ٚعٛد رؤِ١ٓ طؾٟ       (ٔوُ / لا)  :
 ؽىِٟٛ
 خبص
 غ١ش ِؤِٓ
 
 ِوذي اٌذخً :
 أٚ ألً ) 0002لٍ١ً ( 
 ) 0004 – 0052ِزٛعؾ ( 
 ِزضٚط o اهضة      o
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 ) 0004هبٌٟ ( أوضش ِٓ 
 
 ؽبٌخ اٌزذخ١ٓ :
 غ١ش ِذخٓ
 ِذخٓ
 ِذخٓ عبثك
 
 اٌؾبٌخ اٌظؾ١خ :
 % )001 – 09ِّزبص ( 
 % )09 – 08ع١ذ عذآ ( 
 % )07 – 06ع١ذ ( 
 % )05ػو١ف ( ألً ِٓ 
 % )05ِمجٛي ( 
 
 شذح اٌشثٛ :
 ِزمـوخ
 خف١فخ الاعزّشاس
 ِوزذٌخ الاعزّشاس
 شذ٠ذح الاعزّشاس
 
 ً٘ رغزخذَ أدٚ٠خ ٌولاط اٌشثٛ؟
 ٔوُ
 لا
 
 اعّبء الأدٚ٠خ اٌّغزخذِخ:
 .2.                                           1
 .4.                                           3
 
 شٙش اٌّبػ١خ: 21خلاي 
 وُ ِشح صسد ؿج١جه ثغجت اٌشثٛ؟
 
 وُ ِشح ر٘جذ ٌٍـٛاسئ ثغجت اٌشثٛ؟
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 )TCA( tseT lortnoC amhtsA :)3(xidneppA
 
   ) TCA ( tseT lortnoC amhtsA بٌشثٛ:رم١١ُ ِذٜ اٌغ١ـشح هٍٜ
 
 ِغّٛم إٌمبؽفٟ اٌوًّ, اٌّذسعخ أٚ اٌج١ذ؟ فٟ الأسثوخ اعبث١ن اٌّبػ١خ, وُ ِٓ اٌٛلذ ِٕوه ِشع اٌشثٛ ِٓ الأغبص
 
 –ٌُ ٠ؾذس أثذآ 
 5
 –لٍ١لآ ِٓ الأٚلبد 
 4
 -ثوغ الأٚلبد 
 3
 –ِولُ الأٚلبد 
 2
 1 –عّ١ن الأٚلبد 
 
 خلاي الأسثوخ أعبث١ن الأخ١شح, وُ ِٓ ِشح أطبثه لظٛس فٟ اٌزٕفظ؟
 
 –ٚلا ِشح 
 5
ِشح أٚ ِشر١ٓ فٟ 
 4 -الأعجٛم 
ِشاد فٟ الأعجٛم  6-3
 3 -
ِشح ٚاؽذح فٟ اٌ١َٛ 
 2 –
أوضش ِٓ ِشح فٟ اٌ١َٛ 
 1 –
 
 فٟ اٌزٕفظ, ػ١ك اٌظذسأٚ الأٌُ ) خلاي الأسثوخ أعبث١ن الأخ١شح, وُ ِشح رغججذ أهشاع اٌشثٛ ( اٌظف١ش, اٌغوبي, ػ١ك
 فٟ ا٠مبكه فٟ اٌٍ١ً أٚ فٟ ٚلذ عبثك ِٓ اٌّوزبد فٟ اٌظجبػ؟    
 
 –ٚلا ِشح 
 5
ِشح أٚ ِشر١ٓ فٟ 
 4 -الأعجٛم 
ِشح ٚاؽذح فٟ الأعجٛم 
 3 -
اصٕ١ٓ أٚ صلاصخ ٌ١بي 
 2 –فٟ الأعجٛم 
أسثن ٌ١بي أٚ أوضش فٟ 
 1 –الأعجٛم 
 
 وُ ِشح اعزخذِذ أعٙضح الاعزٕشبق؟ خلاي الأسثوخ أعبث١ن الأخ١شح,
 
 –ٚلا ِشح 
 5
ِشح ٚاؽذح فٟ الأعجٛم اٚ   
 4 –ألً 
ِشر١ٓ أٚ صلاس ِشاد 
 3 -فٟ الأعجٛم 
ِشحٚاؽذح أٚ ِشر١ٓ 
 2 –فٟ اٌ١َٛ 
صلاس ِشاد أٚ أوضش 
 1 –فٟ اٌ١َٛ 
 
 و١ف رم١ُّ ع١ـشره هٍٝ ِشع اٌشثٛ خلاي الأسثوخ اعبث١ن الأخ١شح؟
 
 –ِغ١ـش رّبًِب 
 5
 –ِغ١ـش إٌٝ ؽٍذ ِب  4 -ِغ١ـش ثشىً ع١ذ 
 3
 –ع١ئ اٌغ١ـشح 
 2
غ١ش ِغ١ـش هٍٝ   
 1 –الإؿلاق 
 
 
 
 ِغّٛم إٌمبؽ :
 ) ع١ـشح وبٍِخ                     52(
 ) ع١ـشح ع١ذح                   52-02( 
 ) ع١ـشح عضئ١خ               91-51( 
 ) ع١ئ اٌغ١ـشح 51(ألً ِٓ  
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 .tset ecnerehda noitacideM :)4(xidneppA
 
 ecnerehda noitacideM رم١١ُ ِذٜ الاٌزضاَ ثؤدٚ٠خ اٌشثٛ :
 
 ً٘ ٔغ١ذ ِٓ لجً أْ رؤخز أدٚ٠خ اٌشثٛ؟
 ٔوُ                             
 لا
 
 ً٘ اٍّ٘ذ ِٓ لجً أخز أدٚ٠خ اٌشثٛ؟
 ٔوُ                    
 لا 
 
 رزٛلف هٓ أخز أدٚ٠خ اٌشثٛ؟هٕذِب رشوش ثزؾغٓ , ً٘ 
 ٔوُ                                
 لا  
 
 أؽ١بٔآ, ارا شوشد أْ ؽبٌزه اٌظؾ١خ لذ اعٛأد ثوذ أخز أدٚ٠خ اٌشثٛ, ً٘ رزٛلف هٓ أخز٘ب؟
 ٔوُ                               
 لا 
 
 
 ِغّٛم إٌمبؽ :
 
 ) اٌزضاَ هبٌٟ 0(
 ) اٌزضاَ ِزٛعؾ                       2-1(
 ) اٌزضاَ لٍ١ً4-3(  
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 )5( xidneppA :eriannoitseuq egdelwonk amhtsA
 
 eriannoitseuq egdelwonk amhtsA
 أٞ اٌج١بٔبد اٌزبٌ١خ طؾ١ؾخ ٚأ٠ٙب خبؿئخ:
٠ظجؼ أوضش طوٛثخ خلاي أٞ ٔٛم ِٓ إٌبط اٌز٠ٓ ٠وبْٔٛ ِٓ اٌشثٛ ٠غت هٍ١ّٙزغٕت ِّبسعخ اٌش٠بػخ لأْ اٌزٕفظ  .1
 اٌّغٙٛد اٌجذٟٔ.
 خـؤ  طؾ١ؼ 
 لا ٠ؾزبط ٔٛثخ اٌشثٛ ا٘زّبِب فٛس٠ب. .2
 خـؤ طؾ١ؼ 
 ٠ّىٓ أْ ٠ىْٛ اٌشثٛ لبرٍخ. .3
 خـؤ  طؾ١ؼ 
 
 ٔٛثخ اٌشثٛ رؾذس فغؤح,ثذْٚ عبثك أزاس. .4
 خـؤ  طؾ١ؼ 
 
 شذح اٌّشع.ٕ٘بن اٌوذ٠ذ ِٓ الأدٚ٠خ ٌٍغ١ـشح هٍٝ اٌشثٛ,ثبلاهزّبد هٍٝ  .5
 خـؤ  طؾ١ؼ 
 
 ٚعٛد اٌّٙ١غبد اٌّخزٍفخ رغجت ؽذٚس اٌشثٛ .6
 خـؤ  طؾ١ؼ 
 
 لا ٠ٛعذ هلاط ٌٍشثٛ. .7
 خـؤ  طؾ١ؼ 
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 علاجات الربو
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 .nalp noitca amhtsA :)7( xidneppA
 خطة عمل الربو
 الاعُ:...................................سلُ اٌٙبرف:.............................
 اعُ اٌـج١ت:...........................رٛل١ن اٌـج١ت:.......................... 
 اٌزبس٠خ:................................
 إٌّـمخ اٌخؼشاء: أٔذ ثخ١ش ٚثؤِبْ
 lortnoc mret– gnol٠غت أخز الادٚ٠خ اٌـٛ٠ٍخ اٌّذٜ 
 ):sgurd yrotamalfni-itna(وً ٠َٛ ثبلاػبفخ اٌٝ)  snoitacidem
 
 خزٖ      ِزٝ ٠غت هٍ١ه اخز اعُ اٌذٚاء                  هذد ِشاد أ
 ءاٌذٚا
 …………………………………………………………
 …………………………………………………………
 …………………………………………………………
 …………………………………………………………
 
 
 .دلبئك 5ثخبد لجً اٌزّش٠ٓ ة 4أٚ 2:........................لجً اٌزّش٠ٓ
 
 
 
 
 
 
 
 
 
 
 
 اٌزٕفظ ع١ذ.1
 لا عوبي أٚ أص٠ض.2
 ٠ّىٓ اٌٍوت ٚاٌوًّ.3
 ٠ٕبَ ع١ذا فٟ اٌٍ١ً.4
% 08٠غت اْ ٠ىْٛ  retem wolf kaep.5
 .فّب فٛق
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 إٌّـمخاٌظفشاء:٠ضداد عٛءا
 :أٚلا
 
ِن )  )senicidem feiler kciuqاعزوًّ أدٚ٠خ عش٠وخ اٌّفوٛي 
 الاعزّشاس٠خ  ثؤخز الأدٚ٠خ فٟ إٌّـمخ اٌخؼشاء
أٚ  2  )  )tsinoga 2B gnitca trohs...................................
 دل١مخ 02ثخبد وً  4
 
 
 :صبٔ١ب
 
 اسعن ٌٍّٕـمخ اٌخؼشاء, ارا سعوذ ؽبٌزه اٌٝ ؿج١وزٙب
 أٚ                         
إرا ٌُ رزؾغٓ ؽبٌزه أٚ اصداد عٛءا لا رشعن ٌلؤدٚ٠خ اٌّٛعٛدح فٟ 
 .إٌّـمخ اٌخؼشاء
 :ثً
 2B gnitca-trohs (.........................................خز .1
 .ثخبخبد 4أٚ  2  )tsinoga
اٌ١َٛ /ٍِغُ) )sdiorets laro.......................................اػف.2
 .أ٠بَ) 01-3....................(ٌّذح 
عبهخ ثوذ أخز .............................خلاي /ارظً ثبٌـج١ت لجً .3
 .sdiorets laro
 
 ثوغ ِشبوً اٌزٕفظ.1
 أص٠ض أٚ ػ١ك اٌظذس, عوبي.2
 ِشبوً هٕذ اٌٍوت ٚاٌوًّ.3
 اعز١مبف ثبٌٍ١ً ثغجت اٌشثٛ.4
 وً الاهّبي اٌّـٍٛة هٍّٙب لا ٠غزـ١ن هًّ.5
-% 05رىْٛ ث١ٓ   retem wolf  kaep.6
 %.97
 
 
 إٌّـمخاٌؾّشاء:رٕج١ٗ
 .اٌىض١ش ِٓ اٌّشبوً فٟ اٌزٕفظ .1
 .لا ٠غزـ١ن اٌٍوت ٚاٌوًّ  .2
 .لا رغبهذ  feiler kciuqأدٚ٠خ  .3
 %.05ألً ِٓ   retem wolf kaeP .4
 
 :فٟ ٘زٖ اٌؾبٌخ
 
 gnitca-trohs(....................................خز.1
 .ثخبد 6أٚ4)  )tsinoga 2B
 )sdiorets laro...................................(2
 .ٍِغُ
صُ ارظً ثـج١جه الاْ ٚاهشف أه ِب صٌذ ثبٌّٕـمخ 
 .دل١مخ 51اٌؾّشاء ثوذ 
  18
 اٌولاِبد اٌخـشح
 
 .          اٌزٕفظ فٟ ػ١ك ثغجت ٚاٌؾذ٠ش ٌّشٟا اٌّمذسحهٍٝ هذَ.1
 .اٌشفب٘ؤٚالأكبفشصسلبءاٌٍْٛ.2
 :                                                                                                  ف١ٙز٘بٌؾبٌخ
 .ثبلاعوبف أٚارظً اٌّغزشفٝ اٌٝ ٚار٘ت snoitacidem  feiler kciuqِٓ ثخبد 6 أٚ4 خز
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 خذمات الرعاية الصيذلاوية لمرضى الربو: تدربة عشوائية ومراقبة
 
 
 
  : صابريه عثمان هاخس عليانإعذاد
 
  : الذكتور ماهر الخضورإشراف
 
 ملخص
 
 :هذافالأ
 
اٌظ١ذٌٟ اٌغش٠شٞ فٟ اٌّشػٝ اٌجبٌغ١ٓ  لجً  اٌشهب٠خ اٌظ١ذلأ١خ ِِٓذٜ رؤص١ش اٌٙذف اٌشئ١غٟ ِٓ ٘زٖ اٌذساعخ ٘ٛ ِوشفخ  إْ
 اٌز٠ٓ ٠وبْٔٛ ِٓ اٌشثٛ.
 
 :الطريقة
 
 601ٚ 731خ فٟ ِغزشفٝ اٌّمبطذ. ٚشٍّذ اٌذساعأعش٠ذ اٌذساعخ فٟ اٌو١بداد اٌخبسع١خ ٘زٖ اٌذساعخ دساعخ هشٛائ١خ, 
فٟ اٌض٠بسح الاٌٚٝ,  هٍٝ اٌزٛاٌٟ  )puorg lortnoC(ٚاٌغ١ـشح )puorg noitnevretnI(ِش٠ؼب فٟ ِغّٛهبد اٌزذخً
فٟ  هٍٝ اٌزٛاٌٟ  )puorg lortnoC(ٚاٌغ١ـشح )puorg noitnevretnI(ِش٠ؼب فٟ ِغّٛهبد اٌزذخً101ٚ 221ٚؽٛاٌٟ 
 )puorg noitnevretnI(ِش٠ؼب فٟ ِغّٛهبد اٌزذخً 09ٚ 201شٙش فمذ وبْ هذد اٌّشػٝ ؽٛاٌٟ  21شٙٛس, أِب فٝ  6
خلاي اٌفزشح ِٓ عجزّجش (عٕخ) شٙشا  21٘زٖ اٌذساعخ اٌوشٛائ١خ  ذ ِذحٚوبٔ. هٍٝ اٌزٛاٌٟ  )puorg lortnoC(ٚاٌغ١ـشح
 هٓ ؿش٠ك أسلبَ هشٛائ١خ ثبعزخذاَ اٌىّج١ٛرش.  ثظٛسح هشٛائ١خؽ١ش رُ اخز١بس اٌّشػٝ ، 5102إٌٝ عجزّجش  4102
 
هٓ ؿش٠ك اٌظ١ذلأٟ هٍٝ اٌشهب٠خ اٌظ١ذلأ١خ  ذؽظٍ اٌزٟ)puorg noitnevretnI(رُ رمغ١ُ اٌّشػٝ إٌٝ ِغّٛهخ اٌزذخً
ِزوشاد ٌٍّش٠غ هٓ ؿش٠ك ِوشفخ الأدٚ٠خ اٌزٟ ٠ؤخز٘ب,ٚو١ف١خ اعزوّبٌٙب,ٚاهـبئُٙ  ، ٚرمذ٠ُ اٌّشٛسحثخظٛص ِشع اٌشثٛ 
 أٞ سهب٠خ ط١ذلأ١خ. ٌُٙ رمذَ فٍُ)puorg lortnoC(غ١ـشح ِغّٛهخ اٌأِب اٌشهب٠خ ٚغ١ش٘ب، 
 اْأشٙش، فٟ ؽ١ٓ  3وً  ؽظٍٛ هٍٝ اٌشهب٠خ اٌظ١ذلأ١خ٠ٓ اٌز  )puorg noitnevretnI(ٚرٍمٝ ِشػٝ ِغّٛهخ اٌزذخً
أشٙش ِٓ دْٚ أْ ٠ؾظٍٛ هٍٝ أ٠خ  3رُ عّن اٌّوٍِٛبد ِٕٙب ثشىً سٚر١ٕٟ وً puorg lortnoC(غ١ـشح ( ِغّٛهخ اٌ
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رؾٍ١ً  شٙشا فٟ وً ِٓ اٌّغّٛهز١ٓ. ٚلذ رُ 21ٚ  6ِشٛسح. ٚرُ رغغ١ً إٌزبئظ ِٓ ثذا٠خ اٌض٠بسح ٚخلاي ِزبثوخ اٌّشػٝ  فٟ 
 .(50.0<)p، ٚوبْ ِغزٜٛ اٌذلاٌخ 22إٌغخخ  SSPSاٌج١بٔبد ثبعزخذاَ 
 
 :الىتائح
 
رؾغ١ٓ وج١ش فٟ و١ف١خ الاعزوّبي اٌظؾ١ؼ أْ ٕ٘بن  )puorg noitnevretnI(فٟ ٔٙب٠خ فزشح اٌذساعخ، أكٙشد ِغّٛهخ اٌزذخً
وبْ هذدُ٘ ؽٛاٌٟ  01-7ٔغجخ اٌّشػٝ اٌز٠ٓ ؽظٍٛا هٍٝ ِغّٛم هلاِبد ِب ث١ٓ  اشٙش فبْ 6فٟ لأعٙضح اٌشثٛ ؽ١ش أٔ
 )puorg noitnevretnI(اٌزذخً فٟ ِغّٛهخ 311%)29ٚؽٛاٌٟ ( )puorg lortnoCاٌغ١ـشح (فٟ ِغّٛهخ  13%)03(
ؼذ لٍ١لا اٞ ؽٛاٌٟ شٙش فبْ ٔغجخ اٌّشػٝ اٌز٠ٓ ٠لٙشْٚ رمٕ١خ الاعزٕشبق إٌّبعجخ أخف 21.ٌىٓ فٟ )1000.0=p(ِن ل١ّخ 
, puorg lortnoC(فٟ ِغّٛهخ اٌغ١ـشح (   23%) 5.53ٚ(  )puorg noitnevretnI(فٟ  ِغّٛهخ اٌزذخً 88%) 2.68(
 .)120.0=p(ِن اٌم١ّخ الاؽزّبٌ١خ 
 
فٟ الأعبط أ٠ؼب ثىّ١بد وج١شح فٟ ص٠بسح  )puorg noitnevretnI(فٟ ِغّٛهخ اٌزذخً  tseT lortnoC amhtsAٚلذ صاد 
فٟ  9%) 5.4ٚ ( 91%) 5.51أشٙش ِمبسٔخ ِن اٌشهب٠خ اٌّوزبدح, فبْ ٔغجخ اٌغ١ـشح هٍٝ اٌشثٛ ثظٛسح وبٍِخ وبٔذ ؽٛاٌٟ ( 6
هٍٝ اٌزٛاٌٟ, ِن اٌم١ّخ الاؽزّبٌ١خ  puorg lortnoC(ِٚغّٛهخ اٌغ١ـشح ( )puorg noitnevretnI(ِغّٛهخ  اٌزذخً
 ).200.0<P(
 noitnevretnI(فٟ ِغّٛهخ  اٌزذخً 9%) 8.8شٙش فبْ ٔغجخ اٌغ١ـشح هٍٝ اٌشثٛ لذ أخفؼذ ثؾٛاٌٟ ( 21ٌٚىٓ فٟ 
 ).770.0= Pِن ل١ّخ اؽزّبٌ١خ وج١شح ( puorg lortnoC(فٟ ِٚغّٛهخ اٌغ١ـشح ( 7%) 7.7ٚؽٛاٌٟ ( )puorg
 
 )puorg noitnevretnI(اعخ أْ اٌّشػٝ فٟ ِغّٛهخ اٌزذخًٚفٟ ِذٜ الاٌزضاَ ثؤخز الأدٚ٠خ فؤكٙشد إٌزبئظ خلاي فزشح اٌذس
فٟ ِغّٛهخ  5%) 46.3ٟ٘ ٔفغٙب ٌٚ١ظ ٌٙب أٞ رؾغٓ ٟٚ٘ ؽٛاٌٟ ( puorg lortnoC(ٚاٌغ١ـشح (   
ل١ّخ وج١شح =  pؽ١ش اْ ل١ّخ  puorg lortnoC(فٟ ِغّٛهخ اٌغ١ـشح ( 6%) 6.5ٚ (  )puorg noitnevretnI(اٌزذخً
ؽ١ش اْ   )puorg noitnevretnI(اٌزذخًٕ٘بن رؾغٓ وج١ش فٟ الاٌزضاَ أدٚ٠خ اٌشثٛ فٟ ِغّٛهخ  أشٙش 6، ٌٚىٓ فٟ 637.0
 .3000.0%, ِن ل١ّخ اؽزّبٌ١خ رغبٚٞ 7.41 ٘ٛ الاٌزضاَ
 .
ِن  )puorg noitnevretnI(ٚوّب رش١ش اٌذساعخ ا٠ؼب اْ ٕ٘بن رؾغٓ وج١ش عذا فٟ اخزجبس شذح اٌشثٛ فٟ ِغّٛهبد اٌزذخً  
شٙش ٕ٘بن رؾغٓ وج١ش ٌٍغب٠خ فٟ لٍخ اٌزشدد ٌض٠بسح اٌّغزشفٝ فٟ ِغّٛهخ اٌزذخً  21ٚ  6. ٚفٟ 100.0اٌم١ّخ الاؽزّبٌ١خ = 
 ِمبسٔخ ِن خؾ الأعبط. 1000.0,ؽ١ش أْ اٌم١ّخ الاؽزّبٌ١خ = )puorg noitnevretnI(
 
فٟ ِغّٛهخ اٌغ١ـشح  51%) 1.41ز١ٓ, ؽٛاٌٟ (زّشاس٠خ شذح اٌشثٛ ث١ٓ اٌّغّٛهعٚا٠ؼب ٌُ ٠ىٓ ٕ٘بن اخزلاف وج١ش فٟ ا
 .722.0ِن ل١ّخ اؽزّبٌ١خ رغبٚٞ  )puorg noitnevretnI(فٟ ِغّٛهخ اٌزذخً  22%) 61ٚ ( puorg lortnoC((
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, اِب فٟ  3%) 49.2اٞ ؽٛاٌٟ ( )puorg noitnevretnI(ٕ٘بن رؾغٓ وج١ش عذا فٟ ِغّٛهخ اٌزذخً شٙش 21فٟ ٌٚىٕ
 .100.0ِن اٌم١ّخ الاؽزّبٌ١خ = 01%) 11.11فىبٔذ ؽٛاٌٟ ( puorg lortnoC(ِغّٛهخ اٌغ١ـشح (
 
 ) ٠ِٛب51( اٞ  ؽٛاٌٟ دخٛي اٌّغزشف١بد هذد ا٠بَأخفبع وج١ش فٟ  ٕ٘بن)puorg noitnevretnI(ٚا٠ؼب فٟ ِغّٛهخاٌزذخً
ثم١ّخ ٛ) ٠ِٛ85ِمبثً ( ) ٠ِٛب92( ) ؽٛاٌٟDEفٟ هذد ِشاد دخٛي اٌـٛاسئ (ٚ 30.0 = eulav-P((ثم١ّخ ٛ) ٠ِٛ63ِمبثً (
ٌُٚ ٠ىٓ ٕ٘بن فشق ث١ٓ هذد اٌض٠بساد ث١ٓ .puorg lortnoC((ِمبسٔخ ِن ِغّٛهخ اٌزؾىُ  )10.0 = eulav-P(
ا٠ؼب وبْ ٚ).11.0 =  eulav-P( ؽ١ش اْ puorg lortnoC((اٌزؾىُ  ِغّٛهخٚpuorg noitnevretnI(( ِغّٛهخاٌزذخً
 lortnoC(اٌزؾىُفٟ ِغّٛهخ فٟ ث١ّٕب ٠ِٛب)،  94( اٞ ؽٛاٌٟ ِغّٛهخ اٌزذخًالإلبِخ فٟ اٌّغزشفٝ ألً ثىض١ش فٟ ِذح 
 .٠ِٛب) 421( ؽٛاٌٟ)puorg
 
 الاستىتاج:
 
 ٚرش١ش إٌزبئظ اٌؾبٌ١خ أْ اٌزذخً اٌظ١ذٌٟ ٠ّىٓ أْ ٠ىْٛ ٌٙب رؤص١ش إ٠غبثٟ هٍٝ إٌزبئظ اٌّزوٍمخ ثبٌشثٛ فٟ اٌّشػٝ.
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